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Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus
Abstract
Invasive aspergillosis is a leading cause of morbidity and mortality among immunocompromised
populations and is predicted to cause more than 200,000 life- threatening infections each year.
Aspergillus fumigatus is the most prevalent pathogen isolated from patients with invasive aspergillosis,
accounting for more than 60% of all cases. Currently, the only antifungal agents available with consistent
activity against A. fumigatus are the mold-active triazoles and amphotericin B, of which the triazoles
commonly represent both front-line and salvage therapeutic options. Unfortunately, the treatment of
infections caused by A. fumigatus has recently been further complicated by the global emergence of
triazole resistance among both clinical and environmental isolates, and a large proportion of this
resistance remains unexplained. In this work, we characterize the contributions of previously identified
mechanisms of triazole resistance, including mutations in the sterol-demethylase- encoding gene cyp51A,
overexpression of sterol-demethylase genes, and overexpression of the efflux pump-encoding gene abcC,
among a large collection of highly triazole- resistant clinical A. fumigatus isolates. Upon revealing that
these mechanisms alone cannot substantiate the majority of triazole resistance exhibited by this
collection, we then characterize the direct contribution of two additional efflux pump-encoding genes,
abcA and atrI. Increased expression of abcA and atrI has previously been associated with triazole
resistance in clinical isolates of A. fumigatus, and both of these genes exhibit a high degree of homology
with the well characterized Candida albicans triazole efflux pump-encoding gene, CDR1. However, deletion
of either abcA or atrI in triazole-resistant clinical isolates which overexpress these genes, did not result in
a significant change in triazole susceptibility. Finally, upon demonstrating that the canonical mechanisms
of triazole resistance poorly explain the high level of triazole resistance observed in this collection of
clinical isolates, we subsequently describe the identification and characterization of a novel genetic
determinant of triazole resistance. Mutations in the HMG-CoA reductase encoding gene, hmg1, were
identified in a majority of triazole-resistant clinical isolates in our collection. Introduction of three different
hmg1 mutations, predicted to encode residue alterations in the conserved sterol sensing domain of
Hmg1, resulted in significantly increased resistance to the triazole class of agents. Additionally, correction
of an hmg1 mutation in a pan-triazole-resistant clinical isolate of A. fumigatus with a novel
Cas9-ribonucleoprotein (RNP) mediated system, was shown to restore clinical susceptibility to all triazole
agents. Mutations in hmg1 were also shown to lead to the accumulation of ergosterol precursors, such as
eburicol, by sterol profiling, while not altering the expression of sterol-demethylase genes. Taken together,
the findings described in this work serve to demonstrate that mutations in hmg1 are a common and
significant genetic determinant of triazole resistance in clinical isolates of A. fumigatus."
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ABSTRACT
Invasive aspergillosis is a leading cause of morbidity and mortality among
immunocompromised populations and is predicted to cause more than 200,000 lifethreatening infections each year. Aspergillus fumigatus is the most prevalent pathogen
isolated from patients with invasive aspergillosis, accounting for more than 60% of all
cases. Currently, the only antifungal agents available with consistent activity against A.
fumigatus are the mold-active triazoles and amphotericin B, of which the triazoles
commonly represent both front-line and salvage therapeutic options. Unfortunately, the
treatment of infections caused by A. fumigatus has recently been further complicated by
the global emergence of triazole resistance among both clinical and environmental
isolates, and a large proportion of this resistance remains unexplained.
In this work, we characterize the contributions of previously identified
mechanisms of triazole resistance, including mutations in the sterol-demethylaseencoding gene cyp51A, overexpression of sterol-demethylase genes, and overexpression
of the efflux pump-encoding gene abcC, among a large collection of highly triazoleresistant clinical A. fumigatus isolates. Upon revealing that these mechanisms alone
cannot substantiate the majority of triazole resistance exhibited by this collection, we
then characterize the direct contribution of two additional efflux pump-encoding genes,
abcA and atrI. Increased expression of abcA and atrI has previously been associated with
triazole resistance in clinical isolates of A. fumigatus, and both of these genes exhibit a
high degree of homology with the well characterized Candida albicans triazole efflux
pump-encoding gene, CDR1. However, deletion of either abcA or atrI in triazole-resistant
clinical isolates which overexpress these genes, did not result in a significant change in
triazole susceptibility.
Finally, upon demonstrating that the canonical mechanisms of triazole resistance
poorly explain the high level of triazole resistance observed in this collection of clinical
isolates, we subsequently describe the identification and characterization of a novel
genetic determinant of triazole resistance. Mutations in the HMG-CoA reductase
encoding gene, hmg1, were identified in a majority of triazole-resistant clinical isolates in
our collection. Introduction of three different hmg1 mutations, predicted to encode
residue alterations in the conserved sterol sensing domain of Hmg1, resulted in
significantly increased resistance to the triazole class of agents. Additionally, correction
of an hmg1 mutation in a pan-triazole-resistant clinical isolate of A. fumigatus with a
novel Cas9-ribonucleoprotein (RNP) mediated system, was shown to restore clinical
susceptibility to all triazole agents. Mutations in hmg1 were also shown to lead to the
accumulation of ergosterol precursors, such as eburicol, by sterol profiling, while not
altering the expression of sterol-demethylase genes. Taken together, the findings
described in this work serve to demonstrate that mutations in hmg1 are a common and
significant genetic determinant of triazole resistance in clinical isolates of A. fumigatus.
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CHAPTER 1.

THE EMERGING THREAT OF TRIAZOLE-RESISTANT
ASPERGILLUS FUMIGATUS*
Introduction

Invasive aspergillosis is a leading cause of morbidity and mortality among
immunocompromised patient populations, such as patients receiving solid organ or stem
cell transplants, patients with hematologic malignancies, and those taking
immunosuppressive agents.[1] Aspergillus, the causative agent of invasive aspergillosis,
is a genus of septate, saprophytic mold containing hundreds of identified species. Of
these only Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Aspergillus
niger commonly cause disease in humans, with A. fumigatus representing more than 60%
of all clinical isolates.[2] Worldwide, invasive aspergillosis is conservatively estimated to
cause more than 200,000 life threatening infections each year.[1, 2] Mortality rates range
considerably, from 30- 90%, varying by patient population as well as severity and
duration of immunosuppression.[3-5] Unfortunately, the treatment of infections caused
by A. fumigatus has recently been further complicated by the global emergence of triazole
resistance among both clinical and environmental isolates.[6-9]
The Mold-Active Triazoles
Since the widespread introduction of itraconazole to clinical practice in 1992, the
mold-active triazole antifungals have been utilized as both front-line and salvage
therapeutic agents for the treatment of invasive aspergillosis. Voriconazole is now
considered the therapy of choice, and is available in both intravenous and oral
formulations.[10] Multiple studies comparing the efficacy of voriconazole to that of the
previous standard of care, amphotericin B, have found voriconazole to be more
efficacious and generally safer than either conventional (deoxycholate) or lipid
formulations of amphotericin B.[11, 12] Isavuconazole was recently approved for the
treatment of invasive aspergillosis, after demonstrating non-inferiority to the standard of
care, voriconazole.[4, 10] Isavuconazole, as the prodrug isavuconazonium sulfate, is
available in both intravenous and oral formulations.[13] Posaconazole, often used as
prophylaxis against invasive fungal infections in high-risk patients such as those with
acute myeloid leukemia, is also employed as second-line or salvage therapy for invasive
aspergillosis, and is now available in both intravenous and delayed-release tablet
formulations. Itraconazole is still used commonly worldwide, but its use in invasive
aspergillosis has decreased due to both lower anti-aspergillus potency and the withdrawal
of intravenous formulations from some markets.[10] While all these agents possess a
----------------* Reprinted from final submission with permission. Rybak JM, Fortwendel JR, and
Rogers PD. Emerging threat of triazole-resistant Aspergillus fumigatus. J Antimicrob
Chemother. 2019 Apr 1;74(4):835-842. doi: 10.1093/jac/dky517 By permission of
Oxford University Press.
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triazole active moiety (from which this class of agents gained its name), they can be
grouped into two distinct pharmacophores (Figure 1-1). The compact triazoles such as
voriconazole and isavuconazole consist of a triazole ring linked to aromatic groups such
as difluorobenzine via a four-carbon backbone. While the extended side-chain triazoles,
including itraconazole and posaconazole, possess both a halogenated phenyl ring as well
as a long lipophilic side-chain comprised of five and six membered aromatic rings
terminating in a triazolone group. The structural distinctions between these agents are
thought to contribute to differences in stabilizing interactions sterol-demethylase
enzymes.
Mechanism of Action of the Triazoles
In fungi, ergosterol is a key membrane lipid similar to mammalian cholesterol.
Under normal growth conditions, ergosterol is plentiful in the fungal cell membrane and
contributes to membrane integrity and fluidity, as well the appropriate positioning of
fungal proteins within the membrane. The triazoles exert antifungal activity by blocking a
key enzymatic step in the biosynthesis of ergosterol. Through direct interaction between
N4 of the triazole ring and an iron atom present in the catalytic heme group, the triazoles
competitively inhibit sterol-demethylase enzymes (Figure 1-2). Inhibition of steroldemethylase, such as Cyp51A and Cyp51B in the case of A. fumigatus, leads to the
diversion of ergosterol precursors from the normal biosynthetic pathway and
accumulation of alternative sterols including toxic 14⍺-methylated sterols. It is believed
that this depletion of ergosterol and buildup of 14⍺-methylated sterols ultimately leads to
inhibition of fungal growth.[14]
A. fumigatus possesses two genes which encode homologous but distinct steroldemethylase enzymes, cyp51A and cyp51B. These genes share approximately 60%
sequence identity, however the triazole antifungals have been observed to have
significantly lower binding affinity for the Cyp51A enzyme.[15, 16] This reduced
binding affinity is due in large part to the threonine amino acid present at position 301
(T301) of Cyp51A, which replaces the more common isoleucine residue present at this
position in other fungal sterol-demethylase enzymes (including A. fumigatus
Cyp51B).[17] The intrinsic fluconazole resistance of A. fumigatus appears to be a result
of this single residue substitution. Surveillance studies of the potency of the mold-active
triazoles against A. fumigatus clinical isolates have found isavuconazole, itraconazole,
posaconazole, and voriconazole to all possess clinically relevant activity against A.
fumigatus.[18] In general, the MIC of isavuconazole and itraconazole are higher, with
MIC50 and MIC90 of 1 and 2mg/L, and 1 and 1mg/L, respectively (range 0.128-8mg/L:
isavuconazole, 0.25-4mg/L: itraconazole). While the MIC50 and MIC90 for posaconazole
and voriconazole are typically lower, 0.25 and 0.5mg/L for both agents (range 0.061mg/L: posaconazole, 0.125-2mg/L: voriconazole).[18]
The antifungal activity of the triazoles is concentration dependent. This activity
has been shown to be best predicted by the free AUC to MIC ratio (fAUC:MIC).[19, 20]
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Figure 1-1.

Structures of the clinically relevant triazoles.

Figure 1-2.

Canonical mechanisms of triazole resistance in A. fumigatus.
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In neutropenic murine models of pulmonary aspergillosis, the fAUC:MIC needed to
produce a 90% reduction in fungal burden (1-log reduction) was found to be roughly
twice that of stasis for both posaconazole and isavuconazole. This was true for triazolesusceptible and triazole-resistant isolates.[19, 20] Additionally, the triazoles possess
fungicidal activity at physiologically relevant concentrations against most triazolesusceptible A. fumigatus.[21] However, this fungicidal activity is also concentration
dependent and varies from isolate to isolate.[22] Unlike amphotericin B, the mold-active
triazoles do not possess a clinically relevant post-antifungal effect.[23]
Mechanisms of Triazole Resistance
Considerable research has led to the identification of multiple mechanisms of
triazole resistance among other pathogenic fungi.[24] The most predominant mechanisms
responsible for clinically encountered triazole resistance can be grouped into three
distinct categories; 1) mutations in the sterol-demethylase gene, 2) overexpression of the
sterol demethylase gene, and 3) overexpression of either ATP-Binding Cassette (ABC) or
Major Facilitator Superfamily (MFS) type drug efflux pumps.[24] While relatively less is
understood of the mechanisms of clinical triazole resistance among A. fumigatus, much
of what is known focuses on these three paths to triazole resistance (Figure 1-2).[9, 25,
26]
Mutations in the A. fumigatus Sterol-Demethylase Gene cyp51A
The most commonly identified mechanism of triazole resistance among clinical
isolates of A. fumigatus involves mutations in the sterol-demethylase gene, cyp51A.[8,
27] A great number of these mutations have been identified among both clinical and
environmental isolates originating from across the globe, many of which are uniquely
found in triazole resistant isolates (Figure 1-3).[8, 28, 29] A smaller subset of these
mutations have been shown to directly contribute to triazole resistance through genetic
manipulations in the laboratory setting (Table 1-1).[28, 30-36] Conversely, no mutations
which are associated with clinical triazole resistance have been found in the cyp51B
sterol-demethylase gene at this time.
Mutations in cyp51A associated with triazole resistance are believed to result in
amino acid substitutions which either diminish the binding affinity of triazoles with the
sterol-demethylase enzyme, or alter the enzyme structure in a manner which favors native
substrate conversion and thus ergosterol biosynthesis.[28, 30-36] The majority of the
known resistance associated mutations can be grouped into distinct regions of the steroldemethylase enzyme. The most common and best understood of which, encode amino
acid substitutions occurring along the ligand access channel (residues G54, P216, F219,
and M220) or in residues which are located near the catalytic site (Y121, G138).[15] The
ligand access channel associated residue substitutions have been shown to greatly
decrease A. fumigatus susceptibility to both itraconazole and posaconazole, while having
relatively less impact on voriconazole and isavuconazole susceptibilities.[30, 31, 36] It is
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Tandem Repeat Associated
cyp51A Mutations
TR34/L98H
TR46/Y121F/T289A
TR53
TR53/L98H
Individual cyp51A Mutations
Wild Type
Amino Acid
Residue
Substitution
N22
D
G54

E, K, R, V, W

G138

C, R, S

P216

L

F219

C, I, L, S

M220

K, I, R, T, V, W

A284

T

I367

F

Y431

C, S

G432

A, C, S

G434
T440
G448
F495
Y491

C
A
S
L
H

Figure 1-3. cyp51A mutations associated with triazole resistance.
Residues shown in bold are located along the ligand access channels, residues shown
underlined directly interact with voriconazole.
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Table 1-1.
Triazole*
Voriconazole
Posaconazole
Itraconazole

cyp51A mutations by residue and relative impact on triazole MIC.
Ligand Access Channel Residues
G54
F219
P216
M220
+
++
+
+
+
++
++
++
++

Tandem Repeat Associated Residues
TR34/L98H
TR46/Y121F/T289A
+
++
+
+
++
+

*data for isavuconazole not currently available, -; minimal to no impact on MIC, +;
increase in MIC, ++; large increase in MIC
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believed that this agent specific triazole resistance is a consequence of these amino acid
substitutions interfering with stabilizing interactions between the long hydrophobic side
chains present in itraconazole and posaconazole, but absent in the other two agents.
Conversely, a mutation conferring a tyrosine to phenylalanine substitution at position 121
(Y121F) has been shown to greatly decrease voriconazole susceptibility while having
minimal impact on itraconazole or posaconazole.[32, 34] In x-ray crystallography
experiments voriconazole has been observed to directly interact with tyrosine 121, though
it is unknown if any of the other triazoles also interact with this residue.[15]
In addition to mutations in the open reading frame of the cyp51A gene, sequence
duplications forming a tandem repeat in the promoter region of cyp51A have also been
observed.[37] These tandem repeats do not alter the Cyp51A enzyme itself, but
significantly increase to level of cyp51A gene expression, and in turn the amount of
Cyp51A enzyme which must be inhibited by the triazoles to block ergosterol
biosynthesis.[26] The impact of these tandem repeat associated mutations on triazole
resistance will be further detailed in the subsequent section.
Overexpression of cyp51A
The expression of cyp51A and cyp51B is regulated by a complex system of
interacting transcription factors controlled by environmental conditions such as nutrient
availability and stress. While differences are known to exist in the regulation of
expression of the two sterol-demethylase genes, the majority of research has focused on
cyp51A, which when overexpressed is known to contribute to clinical triazole resistance
in A. fumigatus.[9, 26, 34, 35] It remains unknown if overexpression of cyp51B may also
contribute to clinical resistance, but triazole-resistant clinical isolates of A. fumigatus
have been observed to demonstrate increased expression of cyp51B.[38, 39]
The positive-regulation of cyp51A expression is controlled by the sterol regulatory
element binding protein SrbA, which binds to the promoter region of cyp51A at two
specific binding sites as a homodimer (Figure 1-4A). One of these two binding sites is
negatively-regulated by both the multimeric CCAAT-binding complex (CBC)
transcription factor (comprised of HapB, HapC, and HapE) and the iron responsive basic
region leucine zipper transcription factor, HapX. It is believed that under environmental
conditions that favor repression of ergosterol biosynthesis and thus repression of steroldemethylase expression, the CBC and HapX cooperatively bind directly upstream of the
3’ SrbA binding site and diminish the ability of SrbA to promote cyp51A expression. In
the absence of either SrbA or the SrbA binding sites in the promoter region of cyp51A,
cyp51A expression is essentially absent and A. fumigatus becomes hyper-susceptible to
the triazoles.[26]
Two distinct mechanisms leading to overexpression of cyp51A have been
identified in triazole-resistant clinical isolates of A. fumigatus. By far the most prevalent
is the formation of a tandem repeat in the promoter region of cyp51A.[8, 27] Three
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Figure 1-4. Regulation of cyp51A expression.
A) Regulation of cyp51A expression with SrbA homodimers under normal repression of
CBC and HapX. B) Regulation of cyp51A expression in the presence of a tandem repeat
mutation creating two additional SrbA binding sites not effectively repressed by the CBC
and HapX. C) Regulation of cyp51A expression in the presence of CBC containing the
mutant HapEP88L, which is unable to effectively repress the SrbA mediated expression of
cyp51A.
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versions of this tandem repeat sequence have been observed (TR34, TR46, TR53).[33, 37,
40] Each version differs in the length of the repeated sequence (34- 53 bases), but all
result in the formation of two additional SrbA binding sites which are not effectively
regulated by the CBC or HapX (Figure 1-4B). Thus, cyp51A expression is increased by
2-fold or more, and triazole MIC subsequently increase by approximately 4-fold.[26]
Additionally, the TR34 and TR46 variations are, with only one known isolate being the
exception, universally found in conjunction with specific mutations in the cyp51A gene
itself, resulting in the amino acid substitutions L98H and Y121F/T289A,
respectively.[32] Isolates possessing these mutations are often referred to as either having
the TR34/L98H or TR46/Y121F/T289A genotype, and are most commonly observed to be
multi- or pan-triazole-resistant. Worryingly, the prevalence of these tandem repeat
mutations in both environmental and clinical isolates appears to be increasing around the
world.[6, 8, 27, 37, 40]
In addition to alterations of the cyp51A promoter region, a single mutation in the
hapE gene, encoding a subunit of the CBC multimer, has been shown to directly result in
increased cyp51A expression. This mutation was originally identified in an isogenic pair
of clinical isolates where resistance developed on triazole therapy, and results in a P88L
amino acid substitution in HapE.[9] CBC containing the mutant HapEP88L subunit bind
less effectively to the promoter region of cyp51A. Thus, cyp51A expression, driven by the
unimpeded SrbA, is increased (Figure 1-4C). Similar to what is observed with the
tandem repeat cyp51A genotypes, this mutation in hapE leads to a 2-fold or greater
increase in cyp51A expression and increases in MICs of all triazole that have been
tested.[26] While screening for this hapE mutation is not commonly performed, to date
this mechanism of triazole resistance has only been identified in the original clinical
isolates of A. fumigatus from which it was discovered.
Overexpression of Drug Efflux Pumps
In other pathogenic fungi, efflux pump overexpression has been shown to
contribute to clinical triazole resistance. The A. fumigatus genome is predicted to contain
more than 300 efflux pumps, many of which have been observed to have their expression
induced by exposure to the triazoles.[25] Furthermore, a number of these pumps have
been observed to be constitutively overexpressed among triazole-resistant clinical
isolates.[25, 41] However, at present relatively little is known about which of these efflux
pumps contribute to clinical triazole resistance. In triazole-susceptible laboratory strains
of A. fumigatus, the individual disruption of six drug efflux pump genes (abcA, abcC,
atrF, atrI, mdrA, and mdr1) has been observed to increase triazole susceptibility.[25, 4246] However, only the efflux pump gene, abcA, has been demonstrated to contribute to
triazole resistance when constitutively overexpressed in a triazole-susceptible laboratory
strain of A. fumigatus.[45] Additionally, abcC is the only efflux pump gene which has
been demonstrated to contribute to clinical triazole resistance. This ABC efflux pump of
the G- subfamily is a close homolog of well characterized drug efflux pumps from other
species of pathogenic fungi and has been observed to be overexpressed in a number of
triazole-resistant clinical isolates of A. fumigatus. Disruption of abcC in a triazole-
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resistant clinical isolate of A. fumigatus decreased the itraconazole MIC by greater than
4- fold, while voriconazole and posaconazole susceptibility remained unchanged. This
clinical isolate was observed to exhibit increased constitutive expression of abcC (>5
fold) relative to the susceptible reference strain.[25] Drug efflux pumps, have therefore
been proven to be a mechanism by which triazole resistance is mediated in clinical
isolates of A. fumigatus. However, the genetic determinants of drug efflux pump
overexpression in A. fumigatus remains elusive. Recently, the zinc-cluster transcription
factor AtrR was found to promote the expression of both cyp51A and abcC. AtrR is a
close homolog of the Saccharomyces cerevisiae pleotropic drug response zinc-cluster
transcription factor PDR1, and A. fumigatus strains with atrR disrupted exhibit a dramatic
reduction in expression of both abcC and cyp51A.[46] However, the presence of
activating mutations in atrR among triazole-resistant clinical isolates has yet to be
identified, and its direct role in clinical triazole resistance remains unclear.
Emerging Mechanisms of Triazole Resistance
In addition to the aforementioned canonical mechanisms of triazole resistance,
additional potential pathways to resistance in A. fumigatus are beginning to be identified.
The most notable of which are directly linked to the ergosterol biosynthetic pathway.
Two different studies investigating mutations acquired in laboratory strains of triazolesusceptible A. fumigatus which develop triazole resistance upon triazole exposure have
been successful in identifying novel resistance mechanisms. In these experiments,
mutations in the hmg1 gene were found to confer resistance to voriconazole, itraconazole,
and posaconazole (isavuconazole was not tested). The hmg1 gene, encodes an A.
fumigatus homolog of 3-hydroxy-3-methyl-glutaryl (HMG) coenzyme A reductase, a key
enzyme involved in both ergosterol and siderophore biosynthesis.[47] Additionally, a
mutation in the cox10 gene, required for the normal biosynthesis of heme, was found to
directly contribute to triazole resistance. Heme is utilized by a number of ergosterol
biosynthetic genes, including cyp51A and cyp51B, to catalyze enzymatic conversion of
sterols. The mutation in cox10 was observed to significantly reduce itraconazole
susceptibility, yet voriconazole susceptibility was not clearly impacted.[48] While the
roles of these mutations in clinical triazole resistance is currently unknown, these
mutations serve to demonstrate the potential impact of non-canonical mechanisms on the
clinical utility of the triazole antifungals and future screening for such mutations among
clinical isolates of A. fumigatus may be merited.
Epidemiology of Triazole Resistance
Triazole resistance among A. fumigatus isolates emerged as early as the 1980’s in
immunocompromised patients from the United States receiving itraconazole as an
investigational agent. Subsequently, resistant isolates were recovered from patients in the
1990’s in the Netherlands and France. However, in each of these instances, the
identification and reporting of triazole resistance followed years after the original clinical
cases where the isolates were cultured.
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Today, analysis of the prevalence of triazole resistance among A. fumigatus
remains limited by challenges in isolating Aspergillus from clinical specimens, as well as
the additional resources and expertise required to perform antifungal susceptibility testing
of molds.[49] However, triazole-resistant A. fumigatus are nonetheless being reported
around the world in increasing numbers.[8, 50-53] A recent study examining the genetic
diversity of A. fumigatus isolates observed that 6% of the 2,026 isolates obtained from 13
countries spanning four continents, were triazole-resistant.[54] This resistance appears to
vary dramatically by both geographic region and patient population.
Both the increase in overall prevalence of triazole resistance and the variation in
its distribution are perhaps best exemplified in epidemiology data from the Netherlands,
where surveillance has been conducted since the first recovery of resistant clinical
isolates. In the Netherlands, triazole resistance was originally observed to be present in
1.8% of A. fumigatus isolates collected from 1945 to 1998. Subsequently, examination of
resistance rates across seven Dutch university medical centers from 2007- 2009 found the
average triazole resistance rate to have risen to 4.6%, with medical center specific rates
ranging from 0.8% to 9.5%.[7, 51] No seasonal variation in resistance was observed and
there was no clear geographic influence on the distribution of resistance. Importantly, the
vast majority of triazole-resistant isolates were resistant to both itraconazole and
voriconazole, and the case-fatality rate among patients with triazole-resistant disease was
88%. Triazole resistance has also been observed to be more prevalent among certain
high-risk patient populations. When resistance rates were tracked specifically among
hematology patients at two Dutch medical centers, the prevalence of triazole resistance
was found to be dramatically greater than that of the general population, ranging from 17
to 30%.[55] Similar findings were also reported in a single center study of Dutch
intensive care unit patients with invasive aspergillosis, where 26% of isolates were
triazole-resistant.5 Overall 90-day mortality of patients with triazole-resistant disease was
100% in this population.
In the United States, triazole resistance among A. fumigatus is now being reported
in isolates of both clinical and environmental origin.[6, 8, 56] However, only one large,
passive, surveillance study of triazole resistance among US A. fumigatus isolates has been
performed to date. In this study 1,026 isolates were screened and 51 (5%) were found to
have itraconazole MIC above the EUCAST breakpoint for susceptible (CLSI has not
published triazole breakpoints for A. fumigatus).[57] Voriconazole susceptibility was not
reported. More recently, a study characterizing triazole-resistant isolates from the US
performed extensive antifungal susceptibly testing on isolates collected from 2001 to
2015. Of 26 triazole-resistant A. fumigatus clinical isolates tested, all were resistant to
both itraconazole and posaconazole (applying EUCAST breakpoints), and only seven and
eight, respectively, were susceptible to isavuconazole and voriconazole. Additionally,
although the use of agricultural sterol-demethylase inhibitors is less common in the US
than other parts of the world, a study conducted by collecting environmental samples
from peanut fields being treated with triazole agents found 56 of 200 recovered isolates
(28%) were triazole-resistant.[6]
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The distribution of identifiable mechanisms contributing to triazole resistance also
appears to vary dramatically by geographic region. In the Netherlands, as well as other
European and Asian countries such as the United Kingdom and India, the vast majority of
triazole-resistant isolates share at least one common resistance mechanism, comprised of
specific combinations of mutations in the sterol-demethylase gene cyp51A in conjunction
with the formation of tandem repeats in the cyp51A promoter region (TR34/L98H or
TR46/Y121F/T289A genotype).[27] While many of these isolates likely possess
additional resistance mechanisms, as suggested by the varying degrees of agent specific
triazole resistance, the predominance of the TR34/L98H and TR46/Y121F/T289A
genotypes among these resistant isolates cannot be overlooked. Conversely, in the United
States only a small number of clinical isolates have been reported to possess this
particular resistance mechanism. Of the 26 isolates in the aforementioned
characterization of triazole-resistant A. fumigatus isolates, only two TR34/L98H and two
TR46/Y121F/T289A genotype isolates were found. Yet, 16 isolates possessed other
identifiable mutations in cyp51A. This discordance in prevalence of the TR34/L98H and
TR46/Y121F/T289A genotypes has been linked to differences in the application of
triazole related agricultural fungicides. Supporting this link, the TR34/L98H and
TR46/Y121F/T289A genotypes are most prevalent among clinical and environmental
samples from regions with higher utilization of these fungicides, and in vitro studies have
demonstrated rapid acquisition of these and other cyp51A mutations upon exposure to
agricultural triazoles. Notably, of the 56 triazole-resistant environmental samples from
US peanut farms treated with triazoles, 21 (37.5%) were found to possess the TR34/L98H
genotype.[6] This has led some experts to call for a reduction in the reliance on
agricultural sterol-demethylase inhibitors in an effort to preserve the utility of the clinical
agents.[58]
While the identification and study of potential risk factors for triazole-resistant
aspergillosis has been limited by the general paucity of susceptibility data available for
clinical isolates, a small number of patient populations have been associated with higher
prevalence of triazole-resistant aspergillosis. Multiple studies have observed rates of
triazole-resistant A. fumigatus isolates from hematology-oncology patients in Europe,
approximating and even exceeding 20%, however it is important to note that rates more
similar to the general prevalence of resistance have been observed at other institutions.
While prolonged use of prophylactic triazole is not uncommon in this patient population,
these studies have also noted recovery of triazole-resistant isolates from patients with no
prior triazole exposure, suggesting other patient factors possibly in conjunction with
environmental acquisition of triazole-resistant isolates may be involved.[52, 55, 59, 60]
Additionally, two epidemiologic studies examining the rates of triazole-resistant A.
fumigatus among patients being treated in the intensive care units have also reported
higher rates of resistance.[5, 59] Though both of these studies examined patients from
medical centers in the Netherlands where environmental rates of triazole resistance are
known to be high. It has been suggested that increased rates of triazole resistance among
environmental isolates of A. fumigatus, may also increase the risk for triazole resistance
among cases of aspergillosis.[61] This concept of environmental acquisition of resistant
isolates is supported by a report of a patient admitted to the intensive care unit, with no
prior history of antifungal drug exposure, suffering from proven invasive aspergillosis
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caused by an A. fumigatus isolate harboring the TR46/Y121F/T289A genotype.
Environmental screening of the patient’s home garden and household revealed multiple
samples of a genetically indistinguishable and triazole-resistant A. fumigatus.[62]
Conclusions
The mold-active triazoles are essential to both prophylaxis and treatment of
invasive aspergillosis, and few therapeutic alternatives exist. While the overall prevalence
of triazole resistance among clinical isolates of A. fumigatus is currently observed to
range between 1 and 10%, these estimates are limited by a relative paucity of clinical
samples with accompanying susceptibility data. Additionally, the recent dramatic
increase in reports of resistant isolates from both clinical and environmental sources
worldwide is of clear concern. Mutations in cyp51A, overexpression of cyp51A, and
efflux pump gene overexpression all are known to contribute to resistance, yet much of
the triazole resistance among A. fumigatus still remains unexplained. Also lacking is
clinical experience with therapeutic options for the treatment of triazole-resistant A.
fumigatus infections, and mortality associated with these infections remains unacceptably
high. Thus, further research is greatly needed to both better understand the emerging
threat of triazole-resistant A. fumigatus, and to develop novel therapeutic strategies to
combat these resistant infections.
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CHAPTER 2.

CHALLENGING THE PARADIGM OF CLINICAL TRIAZOLE
RESISTANCE IN ASPERGILLUS FUMIGATUS*
Introduction

Aspergillus fumigatus is the predominant pathogen isolated from patients with
invasive aspergillosis, the most common human invasive mold infection. Invasive
aspergillosis is responsible for more than 200,000 life-threatening infections each year,
and afflicts up to 10% of patients with acute leukemia as well as patients receiving stem
cell or solid organ transplantation.[1, 60, 63] Unfortunately, the mortality rates associated
with invasive aspergillosis remain unacceptably high, often exceeding 50%, even when
appropriately diagnosed and treated.[3-5, 60]
Contributing to the poor outcomes associated with the treatment of invasive
aspergillosis is the relative paucity of clinically available antifungal agents with
demonstrated clinical efficacy. Of the four major classes of antifungals, only the triazoles
and amphotericin B are recommended as monotherapy for the treatment of aspergillosis,
with the latter relegated to second-line or salvage treatment due to significant toxicities
and the lack of oral formulations.[10] The triazole class of antifungals therefore have
proven essential to the treatment of invasive aspergillosis, comprising both frontline
treatment options such as voriconazole and isavuconazole, as well as salvage options
such as posaconazole and itraconazole.[10] These agents are generally accepted to exert
fungicidal activity against Aspergillus through the competitive inhibition of steroldemethylase, encoded by the genes cyp51A (Afu4g06890) and cyp51B (Afu7g03740) in
A. fumigatus, which results in abrogation of the synthesis of ergosterol, the major fungal
membrane sterol.[14, 15, 64, 65] However, the treatment of invasive aspergillosis has
recently been further complicated by the global emergence of triazole-resistant disease.
Over the past decade, triazole resistance among clinical isolates of A. fumigatus has been
increasingly reported on six continents, with resistance rates exceeding 20% now being
reported in some studies.[6-8, 30]
Considerable research has led to the identification of three distinct molecular
pathways to clinical triazole resistance in A. fumigatus. These three paths largely mirror
the established mechanisms of resistance previously identified in other pathogenic fungi
such as Candida albicans; 1) mutations in the sterol-demethylase gene cyp51A, 2)
overexpression of the sterol-demethylase gene cyp51A, and 3) overexpression of the
efflux pump-encoding gene abcC [9, 25, 26, 28, 31, 32, 34-36, 66]. However, it remains
unknown to what extent these mechanisms explain the degree of triazole-resistance
observed among clinical isolates of A. fumigatus, and resistant clinical isolates exhibiting
----------------* Modified from final submission with permission. Rybak JM, Ge W, Wiederhold NP,
Parker JE, Kelly SL, Rogers PD and Fortwendel JR. Mutations in hmg1, challenging the
paradigm of clinical triazole resistance in Aspergillus fumigatus. MBio. 2019 Apr
2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19.
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none of these three mechanisms have been repeatedly identified.[25] Thus, the molecular
mechanisms underpinning much of the clinical resistance to this essential class of antiAspergillus agents remains unexplained, limiting the discovery of therapeutic strategies
to overcome triazole-resistant aspergillosis.
In this work, we perform a comprehensive characterization of the direct
contributions of previously identified mechanisms of triazole resistance in a large
collection of triazole-resistant clinical isolates of A. fumigatus. We correct cyp51A
mutations in 10 different triazole-resistant clinical isolates using a novel Cas9-mediated
transformation system to delineate the direct impact these mutations have on clinical
triazole susceptibility, and we assess the potential impact of overexpression of cyp51A,
cyp51B, and abcC on triazole susceptibility in a collection of 21 triazole-resistant clinical
isolates. We subsequently demonstrate that these mechanisms alone fail to explain the
resistance observed in this collection, suggesting the presence of additional mechanisms
of clinical triazole resistance yet to be identified.
Materials and Methods
Isolates, Media, and Growth Conditions Used
Twenty-one previously characterized multi-triazole-resistant clinical isolates of A.
fumigatus, and five triazole-susceptible control clinical isolates of A. fumigatus,
originating from the United States were obtained from the Fungus Testing Laboratory at
the University of Texas in San Antonio. The laboratory strains akuBKU80 and Af293 were
obtained from the Fungal Genetics Stock Center. All strains and clinical isolates used in
this study were maintained on glucose minimal media (GMM) agar at 37°C.
Transformants were selected for using sorbitol (1.2M) supplemented GMM agar (SMM)
containing 150mg/L of hygromycin. All conidia were harvested in sterile water from
three-day-old growth plates and conidia were enumerated visually using a
hemocytometer.
Whole Genome Sequencing
For each isolate, genomic DNA was extracted using the Qiagen DNeasy Plant
Mini Kit as previously described.[67] DNA concentrations were quantified using both the
Qubit Fluorometer and Nanodrop spectrophotometer using the manufacturers’ protocols.
Whole genome libraries were prepared and sequenced at the University of Tennessee
Health Science Center Molecular Resource Center. Bioinformatics services were
provided by code4DNA (www.code4DNA.com). Sequence reads for each sample were
aligned using the STAR sequence alignment tool (v2.5.0b) to the A. fumigatus reference
sequence (version A_fumigatus_Af293_version_s03-m05-r05) which was downloaded
from http://aspgd.org/. Duplicate alignments were marked using Picard (v1.119) and
variants were called using Freebayes (v1.1.0) using the haploid population-based model.
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The Freebayes output vcf file was split into individual sample vcf files using bcftools
(v1.3) and variants for each sample were annotated with snpEff (v4.2) using the A.
fumigatus reference sequence annotations.
Construction of Promoter Replacement Repair Templates and Cas9-RNP for
cyp51A, cyp51B, and abcC
The plasmid pJMR2 was constructed by cloning the proximal 1kb of the promoter
sequence from the A. fumigatus heat shock protein-encoding gene, hspA, into the plasmid
pCR-HygR.[67] Then promoter replacement transformation repair templates for cyp51A,
cyp51B, and abcC were created by PCR using primers (Table 2-1) which amplified both
the hygromycin resistance cassette and the hspA promoter from the plasmid pJMR2,
while also introducing approximately 40 bases of homology targeting sequences
immediately upstream and downstream of the start codon for the respective gene of
interest. PCR products were subsequently purified using the Gene Clean II Kit (MP
Biomedicals). Cas9-RNP complexes targeting sequences immediately upstream of the
open reading frame of each gene of interest were assembled as previously described.[67]
Assessment cyp51A, cyp51B, and abcC Expression by RTqPCR
For assessment of expression in clinical isolates, conidia from each isolate were
allowed to germinate overnight in Aspergillus minimal media incubated at 37°C on an
orbital shaker at 250 RPM. For assessment of expression in constitutive overexpression
strains constructed in the akuBKU80 background, conidia from each isolate were allowed
to germinate overnight in Aspergillus minimal media incubated at 37°C on an orbital
shaker at 250 RPM, then transferred to fresh Aspergillus minimal media either with
voriconazole 0.125mg/L (treated) or without voriconazole (untreated) for an additional 6
hours at 37°C on an orbital shaker at 250 RPM. Then RNA was extracted from mature
hyphae following liquid nitrogen crush as previously described.[68] The RevertAid RT
kit (Thermo Scientific) was utilized to synthesize cDNA. PCR master mix and SYBR
were utilized to amplify A. fumigatus cyp51A, cyp51B, and abcC from cDNA by PCR per
the manufacturer’s instructions. Table 2-1 lists the gene specific primers used for PCR.
Conditions used for PCR were as follows: AmpliTaq Gold activation at 95°C for 10
minutes, 40 cycles of denaturation at 95°C for 15 seconds and annealing/ extension at
60°C. The dissociation curve and threshold cycle (CT) was determined using the CFX96
Real Time PCR system (Bio-Rad). Changes in gene expression among isolates were then
calculated using the 2-ΔΔCT method. All experiments were performed in triplicate from
biological triplicates. As previously described, ΔCT values were used to calculate the
standard error.[68] Statistical analysis was performed using unpaired, two-tailed, students
t-test in Prism 8 for Mac OS by GraphPad Software Inc. with significance set at 0.05 and
degrees of freedom equal to 10.
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Table 2-1.

Oligonucleotides used for cyp51A, cyp51B, and abcC experiments.

Oligo Type
PCR Primers

Gene

Primer Name

Sequence (5'- 3')

cyp51A

cyp51A KI F CRISPR

cyp51A

cyp51A KI R CRISPR

cyp51A

cyp51A OE hspA F

cyp51A

cyp51A OE hspA R

cyp51B

cyp51B OE hspA F

cyp51C

cyp51B OE hspA R

abcC

abcC OE hspA F

abcC

abcC OE hspA R

hphR

hphR screen R

GAATACTGGGCAGCGGGCTGGAGATACT
ATGGCTTTCATATGTTGCTCAGCGTCAGC
ATTCTGAAACACG
CCAGTAAGGTCTGAATAAGGGTTCAATA
CAGTCATTTATTAGGCCCTCGATTCGAGC
TCCCAAATCTGTCCAG
CATTTCCCTCATCACTGCAACTCTAATCC
TCGGGCTCACCCAGCTTGCATGCCTGCA
GG
ACGGCCATGTAGGCCGTAAGCCATAGCA
TCGGCACCATGCTTGGTACCTGTGAAGA
AGTG
CTACCTTTATTCCCTGCGACAGTAACTCG
GTTGATCGATTTGAGCTTGCATGCCTGCA
GG
TTGCAGATGCCGTCGAGAATGAACGCGA
TGAGACCCATGCTTGGTACCTGTGAAGA
AGTG
GTTCGACTGTTTATGTGTATACCTATTGT
GACGCAACCACTCAGCTTGCATGCCTGC
AGG
GGGTTGATGTTAGGATTTATCGTCCCTAG
AAGAGACATGCTTGGTACCTGTGAAGAA
GTG
CAAATCGCCCGCAGAAGCG

crRNA Guide Sequences
cyp51A

cyp51A 5’ crRNA

GGCTTTCATATGTTGCTCAG

cyp51A

cyp51A 3’ crRNA

TTCAAAGGATTTGGTGTGAT

cyp51A

cyp51B 5’ OE crRNA

CTCCCTGTGTCTCCTCGAAA

cyp51B

cyp51B 5’ OE crRNA

TATTCCCTGCGACAGTAACT

abcC

abcC 5’ OE crRNA

GACTGAGTGTCTCACTCAAT

cyp51A

cyp51A RT F e1

CTTCTTTGCGTGCAGAGA

cyp51A

cyp51A RT R e2

GGGGTCGTCAATGGACTA

cyp51B

cyp51B RT F e1

CTTTTTCGACTGCCGCGC

cyp51B

cyp51B RT R e2

AGGCGTAGTGAGTGGAGA

abcC

abcC RT F e1

CCTGGAGAAGGTCTCAATGTCG

abcC

abcC RT R e2

GGCCAGACGTAGGCTCATCC

RTqPCR Primers
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Construction of Allele Replacement Repair Templates and Cas9-RNP for the
cyp51A Locus
The plasmid pCyp51A-HygR was created by cloning the proximal 1.5kb of
promoter sequence and open reading frame of the wild-type cyp51A allele from the
genomic reference strain Af293, upstream of the hygromycin resistance cassette in the
plasmid pCR-HygR, and then cloning the proximal 1.5kb of the wild-type cyp51A
terminator downstream of the hygromycin resistance cassette. Then, the cyp51AWT
transformation repair template was created by PCR using primers which amplified the
wild-type cyp51A allele (including 500 bases of promoter sequence), the hygromycin
resistance cassette, and 500 bases of the cyp51A terminator. Cas9-RNP complexes
targeting sequences immediately upstream and approximately 500 bases downstream of
the open reading frame of cyp51A were assembled as previously described.[67] Target
specific guide sequences are listed in Table 2-1.
Aspergillus Protoplast Transformations
Transformation of A. fumigatus protoplasts were performed as previously
described with minor modifications.[67] Approximately 2μg of each portion applicable
transformation repair templates were then mixed with 200 μL of protoplasts, 26.5 μL of
Cas9-RNP complexes, and 25 μL of polyethylene glycol (PEG)-CaCl2 buffer (60%
[wt/vol] PEG 3350, 50 mM CaCl2·H2O, 450 mM Tris-HCl, pH 7.5) as previously
described. Following an incubation on ice for approximately one hour, 1.25mL PEGCaCl2 was added and the mixture incubated for an additional 20 minutes at room
temperature. The mixture was then diluted to a total volume of 3 mL with STC buffer
(1.2 M sorbitol, 7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM
agar plates. Plates were then incubated overnight prior to being overlaid with SMM top
agar (GMM supplemented with 1.2 M sorbitol and 0.7% [wt/vol] agar) supplemented
with hygromycin (final concentration of 150 g/ml), and the plates were incubated at 37°C
for 3 days. Transformants were isolated to separate plates containing selective agar,
genomic DNA extracted, and successful CRISPR/Cas9 editing confirmed by PCR
screens using gene-specific primers and Sanger sequencing.
Clinical Antifungal Susceptibility Testing
Susceptibilities for amphotericin B, voriconazole, isavuconazole, itraconazole,
and posaconazole were determined for all isolates in accordance with CLSI M38-A2
methodology utilizing broth microdilution in RPMI[69]. Each antifungal was obtained
from the appropriate manufacturer. All agents were suspended in dimethyl sulfoxide
(DMSO) for preparation of stock solutions.
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Data Availability
Whole genome sequencing data files for the 26 Aspergillus fumigatus isolates
have been deposited to NCBI SRA under the accession number PRJNA491253.
Results
Mutations in Sterol-Demethylase Alone Poorly Explain Clinical Triazole Resistance
Mutations in the sterol-demethylase gene cyp51A are the most frequently
identified mechanism of triazole resistance in A. fumigatus.[5, 8, 70] We sought to
delineate the proportion of triazole resistance observed in individual clinical isolates
explained by this mechanism. To accomplish this, a collection of 26 clinical isolates of A.
fumigatus originating from the United States were obtained from the Fungus Testing
Laboratory at the University of Texas Health Science Center at San Antonio, including
21 multi-triazole-resistant isolates with previously reported clinical origins and
characterized cyp51A genotypes, and 5 triazole-susceptible control isolates.[8] High
quality genomic DNA was extracted from each of the 26 isolates, whole genome
sequencing was performed targeting a read depth of approximately 100 reads per base
aligned to the Af293 A. fumigatus reference genome assembly, and a total of 48,552
SNPs, insertion or deletions (indels) unique to triazole-resistant isolates were identified
within 8,669 genes with annotations available. Of the 21 triazole-resistant isolates in this
collection, 16 were identified as possessing peptide sequence altering cyp51A mutations
unique to resistant isolates. Conversely, no unique cyp51B mutations were identified. We
selected 10 of these 16 isolates with cyp51A mutations, which also exhibited resistance to
all clinically available triazole agents, for correction of the cyp51A sequence to that of the
wild-type consensus sequence. These isolates included examples of previously
characterized cyp51A mutations (TR34/L98H, TR46/Y121F/T289A, G448S), mutations at
residues where alternative mutations have previously been characterized (G138C and
F219S), and mutations never before characterized to our knowledge (M263I and I367F)
(Table 2-2).[28, 34, 35, 48, 71]
In order to test the direct contribution of these mutations to clinical triazole
resistance in these isolates, the wild-type cyp51A promoter region and open reading
frame from the triazole-susceptible reference strain Af293 was first cloned upstream of
the hygromycin resistance cassette in plasmid pCR-HygR.[67] 1500 bases of the cyp51A
terminator was then cloned downstream of the hygromycin resistance cassette, yielding
the plasmid pCyp51A-HygR. Then, the cyp51AWT transformation repair template was
created by PCR using primers which amplified the wild-type cyp51A allele (including
500 bases of promoter sequence), the hygromycin resistance cassette, and 500 bases of
the cyp51A terminator. Importantly, this repair template extends approximately 200 bases
upstream of the promoter region where characterized regulatory elements and tandem
repeat sequences have been identified.[26] Protoplasts of each of the 10 triazole-resistant
clinical isolates, as well as the well-characterized triazole-susceptible laboratory strain
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Table 2-2.

Triazole MIC of clinical isolates and derivative cyp51AWT strains.

Parent Clinical Isolate or
Derivative cyp51AWT Strain
DI15-117
DI15-117 cyp51AWT

cyp51A Genotype
F219S
WT

Triazole MIC (mg/L)
Voriconazole Itraconazole Posaconazole
2
≥32
2
4
≥32
4

DI15-100
DI15-100 cyp51AWT

M263I
WT

8
8

≥32
≥32

1
0.5

DI15-116
DI15-116 cyp51AWT

TR34/L98H
WT

8
1

≥32
0.25

1
0.125

DI15-102
DI15-102 cyp51AWT

TR34/L98H
WT

8
4

≥32
≥32

2
0.5

DI15-108
DI15-108 cyp51AWT

G138C
WT

4
4

≥32
≥32

1
0.125

DI15-95
DI15-95 cyp51AWT

M263I
WT

16
16

≥32
≥32

2
1

DI15-98
DI15-98 cyp51AWT

I367F
WT

16
16

16
≥32

2
1

DI15-96
DI15-96 cyp51AWT

TR46/Y121F/T289A
WT

≥32
≥32

4
0.5

1
0.25

DI15-106
DI15-106 cyp51AWT

TR46/Y121F/T289A
WT

≥32
8

4
2

1
0.5

DI15-120
DI15-120 cyp51AWT

G448S
WT

≥32
≥32

≥32
≥32

1
1

MIC shown in bold are greater than epidemiologic cutoff values as published by the
Clinical Laboratory and Standards Institute (1mg/L for voriconazole and itraconazole;
0.25mg/L for posaconazole). WT: cyp51A sequence matches the Af293 wild-type
consensus sequence.
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akuBKU80 (CEA17 ΔakuBKU80) which has a wild-type cyp51A allele, were then
transformed with Cas9-ribonucleoprotein (RNP) complexes, consisting of Cas9 protein
and crRNA-trRNA duplexes targeting sequences immediately upstream and downstream
of the cyp51A locus. The resulting transformants were selected on Aspergillus minimal
media containing hygromycin as previously described.[67, 72] Integration of the repair
template at the native cyp51A locus was confirmed by PCR, and acquisition of the
cyp51AWT sequence was verified by Sanger sequencing.
Clinical susceptibility testing was performed for each of the 10 triazole-resistant
clinical isolates and the corresponding cyp51AWT derivative strains for voriconazole,
itraconazole, and posaconazole according to the Clinical Laboratory Standards Institute
M38-A2 standards (Table 1).[69] All of the resistant clinical isolates exhibited triazole
minimum inhibitory concentrations (MIC) consistent with those previously reported for
these isolates under clinical susceptibility testing conditions, and all MIC for each agent
tested were above epidemiologic cut-off values previously reported by CLSI (1mg/L for
voriconazole and itraconazole, 0.25mg/L for posaconazole).[8, 73] Among the cyp51AWT
strains, only one strain (DI15-116 cyp51AWT) was observed to have full restoration of
wild-type triazole susceptibility, and two strains (DI15-96 cyp51AWT and DI15-108
cyp51AWT) were observed to have restoration of wild-type susceptibility to at least one
triazole. Additionally, two strains (DI15-102 cyp51AWT and DI15-106 cyp51AWT) were
observed to have at least one triazole MIC decrease by more than one dilution. Five of
the 10 cyp51AWT derivative strains exhibited no change in susceptibility to any triazole
agent tested. Importantly, replacement of the native wildtype cyp51A allele with the
cyp51AWT cassette in the akuBKU80 background had no effect on triazole MIC. Taken
together, these data demonstrate that while mutations in cyp51A are common among
triazole-resistant clinical isolates of A. fumigatus, and a number of these mutations have
been demonstrated to increase triazole MIC when introduced into a triazole susceptible
background, mutations in cyp51A alone poorly explain the high level of triazole
resistance observed in this collection of clinical isolates.
Analysis of the Expression of the Sterol-Demethylases Genes cyp51A and cyp51B
Among Triazole-Resistant Clinical Isolates.
Triazole-resistant clinical isolates of A. fumigatus exhibiting overexpression of
cyp51A and cyp51B, relative to susceptible comparator isolates, have previously been
reported.[25, 39] Additionally, both the formation of tandem repeats (TR34, TR46, and
TR53) in the promoter region of cyp51A and a mutation (encoding the amino acid
substitution P88L) in hapE, a CCAAT-binding complex protein-encoding gene which
participates in the negative regulation cyp51A expression, have been shown to increase
both cyp51A expression and triazole MICs.[9, 26, 34] Following the observation that
mutations in cyp51A alone do not explain the degree of triazole resistance observed in
this collection of clinical isolates, we sought to evaluate the potential contributions of
sterol-demethylase gene overexpression to clinical triazole resistance. To accomplish
this, each of the 26 clinical isolates in our collection were grown overnight at 37 °C in
Aspergillus minimal media in biological triplicate, and RNA was extracted from mature
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hyphae following liquid nitrogen crush as previously described.[68] Reverse transcription
quantitative-PCR (RTqPCR) was then utilized to quantify the relative expression of both
cyp51A and cyp51B in each of the 21 triazole-resistant clinical isolates as compared to the
expression level observed among the 5 triazole-susceptible control isolates.
The expression of cyp51A and cyp51B in all clinical isolates was compared to the
triazole-susceptible isolate DI16-6 (voriconazole MIC 0.5 mg/L). Among triazolesusceptible control isolates, the expression of cyp51A ranged from 0.5 to 1.6-fold that of
isolate DI16-6 (Figure 2-1A), with isolates DI16-5, DI-16-7, and DI16-9 exhibiting
statistically significant lower expression of cyp51A. While the expression of cyp51A
among triazole-resistant clinical isolates ranged from 0.7 to 3.5 –fold that of the
susceptible comparator isolate. Twelve of the 21 triazole-resistant isolates were observed
to have cyp51A expression that exceeded the highest expression level observed among
triazole-susceptible isolates. Of these 12 isolates, 8 were found to have cyp51A
expression levels statistically greater than the susceptible comparator isolate. This
included 2 isolates (DI15-102 and DI15-116) which possess the TR34/L98H cyp51A
mutation, 2 isolates (DI15-96 and DI15-106) which possess the TR46/Y121F/T289A
cyp51A mutation, and one isolate (DI15-105) which possesses the previously
characterized P88L-encoding mutation in hapE. However, no previously characterized
mutations known to contribute to cyp51A overexpression, were identified in the
remaining 3 isolates. The expression of cyp51B among the triazole-susceptible control
isolates ranged from 0.7 to 1.3-fold that of isolate DI16-6 (Figure 2-1B), with isolate
DI16-8 exhibiting statistically greater expression of cyp51B (1.3 fold). The expression of
cyp51B among triazole-resistant clinical isolates ranged from 0.7 to 2.1-fold that of the
susceptible comparator isolate, with 4 isolates (DI15-95, DI15-97, DI15-102 and DI15108) exhibiting expression of cyp51B exceeding that of the highest expression level
observed among triazole-susceptible isolates, 3 of which (DI15-95, DI15-102 and DI15108) were statistically significant.
Constitutive Overexpression of cyp51B Decreases Triazole Susceptibility
Overexpression of cyp51A has previously been shown to contribute to triazole
resistance, but it remains unknown if overexpression of the paralogous gene, cyp51B, has
a similar effect on triazole susceptibility. We sought to employ a novel Cas9-RNP
mediated promoter replacement system to delineate the direct impact of constitutive
overexpression of cyp51B on triazole MIC. To accomplish this, the previously
characterized, strong, constitutive promoter from the heat shock protein encoding gene,
hspA (Afu1g07440), was cloned upstream of the hygromycin resistance cassette in the
plasmid pCR-HygR.[74] A transformation repair template for the cyp51B promoter
replacement was then constructed by amplifying the hspA promoter and hygromycin
resistance cassette from the resulting plasmid (pJMR2) with primers that introduced
approximately 50 bases of homology for the 3’ end of the native promoter region and the
5’ end of the cyp51B open reading frame. Protoplasts of the well-characterized triazole-
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Figure 2-1. Relative expression of cyp51A and cyp51B among triazole-resistant
clinical isolates.
A) Expression of cyp51A in clinical isolates relative to triazole-susceptible isolate DI166, identified mutations known to contribute to cyp51A overexpression are shown on the
corresponding bar B) expression of cyp51B in clinical isolates relative to triazolesusceptible isolate DI16-6; Triazole-susceptible isolates shown as open bars, triazoleresistant isolates shown as filled bars. Triazole-resistant isolates shown in order of
escalating voriconazole MIC from left to right. Horizontal dotted lines denote highest and
lowest expression level observed among the 5 triazole-susceptible isolates. Comparisons
with the susceptible control isolate DI16-6 with statistically significant (p<0.05) results
are noted with an Asterix.
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susceptible laboratory strain akuBKU80 were then transformed with Cas9-RNP complexes,
consisting of Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately
upstream of the cyp51B start codon, yielding the strain akuBKU80_PhspAcyp51B (Figure
2-2).[75] As a comparator, the same methodology was employed to create the
constitutive cyp51A overexpressing strain, akuBKU80_PhspAcyp51A.
The relative expression of both cyp51A and cyp51B in the strains
akuBKU80_PhspAcyp51A and akuBKU80_PhspAcyp51B was then compared to the parental
akuBKU80 strain under both normal growth conditions and following voriconazole
treatment. Conidia from each strain were growth in Aspergillus minimal media at 37 °C
until germination, and then were transferred to fresh Aspergillus minimal media
containing either no voriconazole, or 0.125mg/L of voriconazole (half of the MIC of the
parental akuBKU80 strain) for an additional 6 hours at 37 °C. RNA was extracted from
each sample as previously described and RTqPCR was performed. The expression of
cyp51B in akuBKU80 was 2-fold higher after treatment with voriconazole than in untreated
conditions (Figure 2-3A). Expression of cyp51B in the akuBKU80_PhspAcyp51B strain was
35.9-fold higher under untreated conditions, and 36.9-fold higher following voriconazole
exposure, as compared to the expression measured in the parental akuBKU80 under
untreated conditions. This increased expression was statistically greater than in the
parental strain under both treated and untreated conditions. The expression of cyp51B in
the akuBKU80_PhspAcyp51A strain approximated that of akuBKU80 under both untreated and
voriconazole-treated conditions. The expression of cyp51A in akuBKU80 was 4.1-fold
higher following treatment with voriconazole as compared to untreated conditions.
Expression of cyp51A in the akuBKU80_PhspAcyp51A strain was 14.1-fold higher under
untreated conditions, and 18.5-fold higher following voriconazole exposure, as compared
to the expression measured in the parental akuBKU80 under untreated conditions. This
increased expression was statistically greater than in the parental strain under both treated
and untreated conditions. The expression of cyp51A in the akuBKU80_PhspAcyp51B strain
was similar to that of akuBKU80 under both untreated and voriconazole-treated conditions.
Upon confirmation of the constitutive overexpression of cyp51A and cyp51B in
the akuBKU80_PhspAcyp51A and akuBKU80_PhspAcyp51B strains, respectively, voriconazole
MIC were performed in triplicate according to CLSI M38-A2 standards.[69] The parental
akuBKU80 strain exhibited a voriconazole MIC of 0.25mg/L. The akuBKU80_PhspAcyp51A
strain was observed to have a 2-fold increase in voriconazole MIC (0.5mg/L), which is
similar to the decrease in susceptibility previously reported when expression of this gene
is increased as a result of either the formation of tandem repeats in the cyp51A promoter
or a mutation in hapE (Figure 2-3B)[9, 26, 34, 35]. Interestingly, the voriconazole MIC
of the akuBKU80_PhspAcyp51B strain was 1mg/L, 4-fold higher than the parental isolate.
Taken together, these results demonstrate that overexpression of either steroldemethylase gene can decrease triazole susceptibility. However, even when the
expression of either of these genes increase by as much as 36.9-fold, MIC did not exceed
the epidemiological cutoff-value for voriconazole reported by CLSI (1mg/L).[73]
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Figure 2-2. Schematic of Cas9-RNP mediated promoter replacement system.
Constitutive overexpression repair templates were amplified from pJMR2 using primers
incorporating microhomology targeting genes of interest (GOI), then mixed with Cas9RNP targeting immediately upstream of the start codon of the GOI, and protoplasts
created from the strain akuBKU80.
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Figure 2-3. Relative expression of cyp51A and cyp51B, and voriconazole MIC in
promoter replacement strains akuBKU80_PhspAcyp51A and akuBKU80_PhspAcyp51B.
The expression of A) cyp51A and cyp51B in akuBKU80, akuBKU80_PhspAcyp51A, and
akuBKU80_PhspAcyp51B was determined by RTqPCR following growth in Aspergillus
minimal media at 37 °C both with voriconazole (0.125mg/L) treatment for 6 hours, and
without voriconazole treatment. The expression level for each sample is shown relative to
that of the respective gene in akuBKU80 without voriconazole treatment. B) Voriconazole
MIC for akuBKU80, akuBKU80_PhspAcyp51A, and akuBKU80_PhspAcyp51B. Comparisons with
statistically significant (p<0.05) results are noted with an Asterix, while those that are not
are noted with “ns”.
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Analysis of the Expression of the Efflux Pump-Encoding Gene abcC Among
Triazole-Resistant Clinical Isolates
In addition to sterol-demethylase-mediated mechanisms of triazole resistance,
increased constitutive expression of the ATP-binding cassette efflux pump encoding
gene, abcC (Afu1g14330; also known as abcB, cdr1B, and abcG1), has been associated
with triazole resistance in A. fumigatus.[25, 48, 66] Furthermore, deletion of abcC in both
triazole-susceptible laboratory strains of A. fumigatus, as well as a triazole-resistant
clinical isolate, has been shown to increase triazole susceptibility.[25, 48, 66] As cyp51A
and cyp51B-mediated mechanisms alone do not adequately explain the high level of
triazole-resistance in this collection of clinical isolates, we sought to characterized the
expression of abcC and its potential impact on triazole susceptibility. To accomplish this,
each of the 26 clinical isolates in our collection were grown overnight at 37 °C in
Aspergillus minimal media in biological triplicate, and RNA was extracted as previously
described. RTqPCR was then utilized to quantify the relative expression of abcC in each
of the 21 triazole-resistant clinical isolates as compared to the expression level observed
among the 5 triazole-susceptible control isolates.
The expression of abcC in all clinical isolates was compared to the triazolesusceptible isolate DI16-6. Among triazole-susceptible control isolates, the expression of
abcC ranged from 0.7 to 2-fold that of isolate DI16-6 (Figure 2-4A), with both isolates
DI16-5 and DI16-8 exhibiting statically greater abcC expression (1.3 and 2.0-fold
respectively) than DI16-6. The expression of abcC among triazole-resistant clinical
isolates ranged from 1.2 to 33.2-fold that of the susceptible comparator isolate. Nineteen
of the 21 triazole-resistant isolates were observed to have abcC expression that was
statistically greater than the expression observed in the susceptible control isolate DI16-6,
14 of which exhibited abcC expression which also exceeded the highest expression level
observed among triazole-susceptible isolates (2-fold). While the majority of these 14
isolates exhibited modestly elevated abcC expression (2.4 to 4.1-fold that of the
comparator susceptible isolate) isolates DI15-110, DI15-120, and DI15-106 exhibited
markedly higher levels of abcC expression (6.5, 10.4, and 33.2-fold, respectively).
Notably, the pan-triazole-resistant isolate DI15-110, which exhibited the highest level of
abcC expression, possesses no mutations in cyp51A and did not exhibit increased
constitutive expression of either sterol-demethylase gene.
As previous studies associating increased triazole resistance to abcC have entirely
relied upon deletion of the abcC gene among either clinical or laboratory isolates of A.
fumigatus, we next sought to utilize our Cas9-RNP mediated promoter replacement
system to delineate the direct impact of constitutive overexpression of abcC on triazole
MIC. To accomplish this, protoplasts of the triazole-susceptible laboratory strain
akuBKU80 were transformed with Cas9-ribonucleoprotein (RNP) complexes, consisting of
Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately upstream of
the abcC start codon, as well as the PhspAabcC transformation repair template which
contains both the hspA promoter and hygromycin resistance cassette flanked by 50-bases
of micro-homology targeting the abcC locus, yielding the strain akuBKU80_PhspAabcC.
Subsequently, the relative expression of abcC in both akuBKU80PhspAabcC and the
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Figure 2-4. Relative expression of abcC in triazole-resistant clinical isolates and
the constitutive overexpression strain akuBKU80_PhspAabcC.
Triazole-susceptible isolates shown as open bars, triazole-resistant isolates shown as
filled bars. Triazole resistant isolates shown in order of escalating voriconazole MIC
from left to right. Horizontal dotted lines denote highest and lowest expression level
observed among the 5 triazole-susceptible isolates. a) expression of abcC relative to
triazole-susceptible isolate DI16-6. b) The expression of abcC in strains akuBKU80 and
akuBKU80_PhspAabcC was determined by RTqPCR following growth in Aspergillus
minimal media at 37 °C both with voriconazole (0.125mg/L) treatment for 6 hours, and
without voriconazole treatment. The expression level for each sample is shown relative to
that of the respective gene in akuBKU80 without voriconazole treatment. Comparisons
with statistically significant (p<0.05) results are noted with an Asterix, while those that
are not are noted with “ns”.
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parental strain akuBKU80 was assessed by RTqPCR following growth in Aspergillus
minimal media at 37 °C both with voriconazole treatment (0.125mg/L) for 6 hours and
without.
In the parental akuBKU80 strain, abcC expression was significantly (9.7-fold)
higher following voriconazole treatment than was observed without voriconazole
treatment (Figure 2-4B). By comparison, the akuBKU80_PhspAabcC strain exhibited 7.8fold and 10.4-fold abcC expression, under untreated and voriconazole-treated conditions,
respectively, as compared to the expression of abcC measured in the parental akuBKU80
under untreated conditions. abcC expression was not found to be significantly different
between akuBKU80_PhspAabcC and the parental strain when both had been treated with
voriconazole for 6 hours. Surprisingly, even with an approximate 10-fold increase in the
constitutive expression of abcC, the akuBKU80_PhspAabcC strain did not demonstrate any
change in voriconazole susceptibility relative to the parental akuBKU80 strain (MIC
0.25mg/L).
Conclusions
In this work, we performed a comprehensive characterization of the direct
contributions of previously identified mechanisms of triazole resistance in a collection of
triazole-resistant clinical isolates of A. fumigatus. We observed that correction of cyp51A
mutations in 10 pan-triazole-resistant clinical isolates only restored wild-type
susceptibility, to even a single triazole agent, in 3 isolates. We then demonstrated that
while constitutive overexpression of cyp51A, and to a lesser extent cyp51B, was common
among isolates in this collection, increasing expression of either sterol-demethylase gene
by as much as 18 to 36-fold in the triazole-susceptible akuBKU80 background, had a
limited effect on triazole MIC. Analogously, we then observed that while the expression
of the ABC-type efflux pump-encoding gene abcC was higher among 14 of the triazoleresistant isolates in this collection, constitutive overexpression of this gene in the
akuBKU80 background did not have any effect on voriconazole MIC.
Taken together, these data serve to demonstrate that while the canonical
mechanisms of triazole resistance, even when considered collectively, do not adequately
explain the triazole resistance observed in this collection of A. fumigatus clinical isolates,
and additional mechanisms yet to be identified are likely present in this collection.
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CHAPTER 3. THE ASPERGILLUS FUMIGATUS EFFLUX PUMP-ENCODING
GENES ABCA AND ATRI ARE NOT SIGNIFICANT CONTRIBUTORS TO
CLINICAL TRIAZOLE RESISTANCE*
Introduction
Aspergillus fumigatus is the principal etiological agent of invasive aspergillosis, a
devastating disease state responsible for more than 200,000 life-threatening infections
each year, and predominantly afflicting the expanding population of
immunocompromised patients.[1, 2] Unfortunately, even among patients appropriately
diagnosed and receiving the best available treatment, clinical outcomes associated with
invasive aspergillosis remain poor with mortality rates ranging from 30-90%.[3-5, 60]
Potentially contributing to these poor outcomes, is the paucity of therapeutic
options for the treatment of invasive aspergillosis. Of the relatively limited
armamentarium of clinically available antifungals, only the triazoles, the echinocandins,
and the polyene amphotericin B, are commonly utilized for the treatment of invasive
aspergillosis. However, amphotericin B is most often recommended as salvage or secondline therapy, because of both limitations in available formulations and a less favorable
safety profile, and the echinocandins are most frequently used as adjunctive therapy due
to a lack of fungicidal activity against Aspergillus.[10] Thus, the anti-Aspergillus
triazoles, including voriconazole, isavuconazole, itraconazole, and posaconazole, have
proven essential to the treatment of invasive aspergillosis, and are commonly relied upon
for both front-line and salvage therapies. Yet, the emergence isolates of Aspergillus
fumigatus from both clinical and environmental samples, represents a critical treat to the
future utility of this crucial class of anti-Aspergillus agents.[5, 6, 8, 37, 52]
Over the last several years, the identification of triazole-resistant A. fumigatus has
been increasingly reported worldwide. In certain regions such as northern Europe, where
the rate of triazole-resistant A. fumigatus had previously approximated the global average
of 5%, resistance rates exceeding 15% are now being reported.[7, 51, 55] While a
growing body of evidence supports the agricultural use of antifungals as a significant
contributor to this emergence of resistance, the underlying molecular mechanisms of
triazole resistance are less well understood.[6, 76-78] The majority of the molecular
mechanisms of triazole resistance which have been characterized to date involve the
genes encoding sterol-demethylase, the enzymes which the triazoles competitively
inhibit.[79] A number of mutations encoding amino acid substitutions in one of the A.
fumigatus sterol-demethylase enzymes, Cyp51A, are known to decrease triazole
susceptibility when introduced into susceptible laboratory strains of A. fumigatus.[79]
----------------* Modified from final submission with permission. Rybak JM, Ge W, Wiederhold NP,
Parker JE, Kelly SL, Rogers PD and Fortwendel JR. Mutations in hmg1, challenging the
paradigm of clinical triazole resistance in Aspergillus fumigatus. MBio. 2019 Apr
2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19

31

Additionally, mutations altering both cis- and trans-regulatory elements controlling the
expression of cyp51A have also been shown to contribute to triazole resistance. However,
in our previous studies we have demonstrated that mutations in cyp51A and
overexpression of sterol demethylase genes cannot explain the high level of triazole
resistance observed among many clinical isolates, suggesting the contribution of
additional mechanisms not yet identified.
Another common mechanism of triazole antifungal resistance in pathogenic fungi
is the up-regulation of efflux pump-encoding gene expression. The A. fumigatus genome
is predicted to contain more than 300 efflux pump-encoding genes, many of which have
been observed to have their expression induced by exposure to the triazoles.[25, 42-44,
66] Furthermore, a number of these transporters have been observed to be constitutively
overexpressed among triazole resistant clinical isolates.[25] In triazole-susceptible
laboratory strains of A. fumigatus, the individual disruption of six efflux pump genes
(abcA, abcC, atrF, atrI, mdr1, and mdrA) has been observed to increase triazole
susceptibility. [25, 42-44, 66] However, only the small molecule transporter gene, abcA,
has been demonstrated to contribute to triazole resistance when constitutively
overexpressed in a triazole-susceptible laboratory strain of A. fumigatus. Additionally,
abcC (also called cdr1B, abcB, and abcG1) is the only transporter gene which has been
demonstrated to contribute to clinical triazole resistance. Disruption of abcC in a triazoleresistant clinical isolate of A. fumigatus decreased the itraconazole minimum inhibitory
concentration (MIC) by greater than 4-fold, while voriconazole and posaconazole
susceptibility remained unchanged. This clinical isolate was observed to exhibit increased
constitutive expression of abcC (>5 fold) relative to the susceptible reference strain.
Efflux pumps have therefore been proven to be a mechanism by which triazole resistance
is mediated in clinical isolates of A. fumigatus. However, the extent of the contribution of
overexpression of these transporters to clinical triazole resistance is not known.
In this work, we identify the A. fumigatus efflux pumps with the highest degree of
homology to C. albicans Cdr1, a well characterized efflux pump known to significantly
contribute to clinical triazole resistance.[80, 81] We then perform transcriptional profiling
on a collection of twenty-one highly triazole-resistant clinical isolates of A. fumigatus as
well as five triazole-susceptible control isolates to identify which of the genes encoding
the identified efflux pumps are differentially expressed among triazole-resistant isolates.
Of these genes, abcA and atrI were identified as the candidates of greatest interest, and
selected for deletion in clinical isolates observed to constitutively overexpress these
genes using a Cas9-mediated gene transformation system. We subsequently demonstrate
that the deletion of either abcA or atrI in highly triazole resistant clinical isolates of A.
fumigatus known to overexpress these efflux pump-encoding genes, is insufficient to
significantly restore triazole susceptibility.
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Materials and Methods
Isolates, Media, and Growth Conditions Used
Twenty-one previously characterized multi-triazole-resistant clinical isolates of A.
fumigatus, and five triazole-susceptible control clinical isolates of A. fumigatus,
originating from the United States were obtained from the Fungus Testing Laboratory at
the University of Texas in San Antonio.[8] All clinical isolates were maintained on
glucose minimal media (GMM) agar at 37°C. Transformants were selected for using
sorbitol (1.2M) supplemented GMM agar (SMM) containing 150mg/L of hygromycin.
All conidia were harvested in sterile water from three-day-old growth plates and conidia
were enumerated visually using a hemocytometer.
Transcriptional Profiling
For assessment of the expression of efflux pump-encoding genes of interest in
clinical isolates, conidia from each isolate were allowed to germinate overnight in
Aspergillus minimal media incubated at 37°C on an orbital shaker at 250 RPM in
biological triplicate. Then RNA was isolated by TriZol based extraction from mature
hyphae following liquid nitrogen crush as previously described.[68] RNA samples were
purified using the Qiagen® RNeasy kit. Barcoded libraries were prepared and sequenced
on the Illumina MiSeq platform. Bowtie2 was utilized to create the A. fumigatus Af293
reference genome index, followed by alignment of RNAseq reads to the reference
genome by TopHat2. Transcript assemblies will then be generated from the aligned
RNAseq reads by Cufflinks, and Cuffmerge was utilized to create a single annotated
transcriptome. Transcript counts from each sample, normalized by reads per kilobase of
exon length per million mapped reads, were then compared to the triazole susceptible
control clinical isolate DI-16-6 (voriconazole MIC 0.25mg/L) to obtain fold change
values. Statistical analysis was performed using unpaired, two-tailed, students t-test in
Prism 8 for Mac OS by GraphPad Software Inc. with significance set at 0.05 and degrees
of freedom equal to 10.
Construction of Efflux Pump-Encoding Gene Deletion Repair Templates
Repair templates consisting of the resistance marker (hphR) and 50 bases of
microhomology targeting the genes of interest were prepared by PCR as previously
described.[67] Briefly, the hygromycin B resistance cassette, including the gdpA
promoter and hphR gene was amplified by PCR from the pUCGH plasmid using primers
that introduced approximately 50 bases of homology with the regions immediately
upstream and downstream of either the abcA or atrI open reading frame. Subsequently,
the Gene Clean II Kit (MP Biomedicals) was used to purify PCR products following
confirmation of product size by gel electrophoresis. Cas9-RNP complexes targeting
sequences immediately upstream and downstream of the open reading frame of abcA and

33

atrI were assembled as previously described.[67] Target specific primers and guide
sequences are listed in Table 3-1.
Aspergillus Protoplast Transformations
Transformation of A. fumigatus protoplasts were performed as previously
described with minor modifications.[67] Approximately 2μg of each portion applicable
transformation repair templates were then mixed with 200 μL of protoplasts, 26.5 μL of
Cas9-RNP complexes, and 25 μL of polyethylene glycol (PEG)-CaCl2 buffer (60%
[wt/vol] PEG 3350, 50 mM CaCl2·H2O, 450 mM Tris-HCl, pH 7.5) as previously
described. Following an incubation on ice for approximately one hour, 1.25mL PEGCaCl2 was added and the mixture incubated for an additional 20 minutes at room
temperature. The mixture was then diluted to a total volume of 3 mL with STC buffer
(1.2 M sorbitol, 7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM
agar plates. Plates were then incubated overnight prior to being overlaid with SMM top
agar (GMM supplemented with 1.2 M sorbitol and 0.7% [wt/vol] agar) supplemented
with hygromycin (final concentration of 150 g/ml), and the plates were incubated at 37°C
for 3 days. Transformants were isolated to separate plates containing selective agar,
genomic DNA extracted, and successful CRISPR/Cas9 editing confirmed by PCR
screens using gene-specific primers.
Clinical Antifungal Susceptibility Testing
Susceptibilities for voriconazole, isavuconazole, itraconazole, and posaconazole
were determined for all isolates in accordance with Clinical Laboratory Standards
Institute (CLSI) M38-A2 methodology utilizing broth microdilution in RPMI in technical
triplicate.[69] Each antifungal was obtained from the appropriate manufacturer. All
agents were suspended in dimethyl sulfoxide (DMSO) for preparation of stock solutions.
Results
Analysis of the Expression of the Efflux Pump-Encoding Genes abcA and atrI
Among Triazole-Resistant Clinical Isolates
To identify candidate efflux-pumps encoding genes which may contribute to
triazole resistance in clinical isolates of A. fumigatus, the genes in the reference Af293 A.
fumigatus genome with a predicted peptide sequences possessing the highest homology
to C. albicans Cdr1 were identified by BLASTP. Twelve genes (Table 3-2) were
identified to have markedly higher homology than any other gene (BLAST P scores
greater than 800, E values of 0.0, and greater than 35% matching residue identities). Of
these, four have been previously associated with triazole resistance in A. fumigatus
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Table 3-1.
Oligo Type
PCR Primers

Oligonucleotides used for abcA and atrI experiments.
Gene

Primer Name

Sequence (5'- 3')

abcA

abcA KO F CRISPR

abcA

abcA KO R CRISPR

atrI

atrI KO F CRISPR

atrI

atrI KO R CRISPR

abcA

abcA screen F

atrI

atrI screen F

hphR

hphR screen R

GTATTTCTTCCTGCCATGACCAGGCAGTCA
TCCCAGAGGTTGAGCTTGCATGCCTGCAGG
CTATCAGTGCTGCAAGTCATGCAGGGTACA
TATACATCACAGCGCCCTTCCGAGCTCCC
CCACTGTGGATTCTCGGCATCGTCATTCAT
TTTTCTTCCGAGCTTGCATGCCTGCAGG
GGCGGCAGGAAAGATGTGGATTTTCTATGT
ATAAGAATAGCGCCCTTCCGAGCTCCC
GTTCGACTGTTTATGTGTATACCTATTGTG
ACGCAACCACTCAGCTTGCATGCCTGCAGG
GGGTTGATGTTAGGATTTATCGTCCCTAGA
AGAGACATGCTTGGTACCTGTGAAGAAGT
G
CAAATCGCCCGCAGAAGCG

crRNA Guide Sequences
abcA

abcA 5’ crRNA

TGGTGTGAGTCGTGCAGCGA

abcA

abcA 3’ crRNA

CTTATTGCTGTTCGTCAGCT

atrI

atrI 5’ crRNA

ATTATGGGTGTATAGATGAA

atrI

atrI 5’ crRNA

CATGTACACACCCACTATCA
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Table 3-2.

Relative expression of efflux pump-coding genes of interest among triazole-resistant clinical isolates.

DI16-5

DI16-9

DI16-8

DI16-7

DI15-111

DI15-99

DI15-107

DI15-109

DI15-115

DI15-103

DI15-117

DI15-118

DI15-97

DI15-114

DI15-100

DI15-110

DI15-116

DI15-105

DI15-102

DI15-108

DI15-95

DI15-98

DI15-96

DI15-106

DI15-120

Resistant Isolates

DI16-6

Susceptible Isolates

Afu2g15130
(abcA)

0.9

1.4

0.6

1.5

1.0

2.1

2.4

0.6

2.1

0.7

4.2

1.7

2.5

1.8

7.4

19.0

238.6

1.4

15.1

1.3

1.1

2.3

3.3

11.6

6.6

1.8

Afu1g14330
(abcC)

0.9

3.1

1.2

1.2

1.5

1.2

0.8

0.8

1.9

0.8

1.4

1.4

1.1

3.1

3.2

3.7

83.4

3.3

2.4

1.9

0.5

1.7

2.4

6.8

4.0

6.3

Afu1g17440

1.1

0.7

0.7

0.3

0.7

1.3

0.8

0.9

2.2

2.5

1.6

1.1

0.4

1.3

2.1

2.3

3.2

1.7

1.6

2.6

8.7

1.7

1.0

1.1

2.6

1.6

0.8

0.5

0.4

1.4

0.6

0.3

0.3

0.4

0.4

0.2

0.3

0.1

0.2

0.4

0.8

1.5

0.6

0.2

0.2

0.2

1.8

1.1

1.2

0.6

0.5

0.2

1.1

0.6

0.8

1.3

0.9

2.0

1.4

1.3

1.2

1.7

0.6

1.5

1.9

1.6

2.1

2.2

8.3

1.8

2.0

3.5

1.7

2.0

2.3

4.6

8.1

3.3

0.9

0.6

0.8

0.7

0.5

1.5

0.5

0.5

0.8

0.3

0.7

0.6

0.7

1.5

0.9

0.9

1.1

1.0

0.9

1.1

1.6

1.3

1.6

1.3

1.4

0.6

1.1

1.5

1.3

1.3

1.6

1.8

1.0

1.0

3.2

1.5

5.6

0.9

2.6

1.3

1.1

1.9

3.6

1.3

22.4

7.9

1.1

3.3

3.4

2.4

6.1

1.4

1.1

0.5

0.6

0.5

0.6

0.7

0.5

0.4

0.6

0.6

0.5

0.6

0.6

0.7

0.4

1.3

2.3

0.7

0.5

1.4

1.0

0.7

0.8

1.8

1.7

1.0

0.9

0.4

2.3

6.9

1.3

2.3

1.4

2.2

4.1

1.6

1.8

1.7

2.3

2.6

2.7

1.2

1.0

3.8

5.3

8.4

4.6

2.0

6.9

4.6

1.6

2.2

1.1

0.3

0.4

0.7

0.6

0.3

0.5

0.8

0.8

0.6

0.6

0.3

0.9

0.3

0.5

0.2

0.8

0.2

1.5

0.5

0.8

0.4

1.4

0.3

0.4

0.5

0.9

0.9

0.9

4.7

1.3

1.1

0.7

0.8

0.9

0.6

0.5

0.2

0.6

1.7

0.3

1.3

0.8

0.4

0.8

0.9

0.8

1.9

0.5

1.4

0.6

0.7

1.1

1.2

1.2

1.2

1.6

0.6

0.8

1.3

1.0

0.9

0.6

0.9

1.2

1.8

1.2

1.4

1.1

1.6

1.6

1.7

1.3

2.2

1.4

1.5

1.7

1.0

Gene (Name)

Afu5g00790
Afu3g07300
(atrI)
Afu5g02260
Afu6g08020
Afu3g01400
Afu6g04360
(atrF)
Afu4g01050
Afu5g09460
Afu8g02650

A. fumigatus clinical isolates are ordered by escalating voriconazole MIC from left to right. A fumigatus genes are listed by degree of
homology with C. albicans Cdr1 from top to bottom. Genes shown in bold have previously been associated with triazole resistance in
A. fumigatus. Fold expression values are shown as the average of three independent biological samples relative to the triazolesusceptible control isolate DI16-6. Fold expression values shown underlined are the highest for that gene among susceptible isolates.
Fold expression values among resistant isolates shown in bold are at least two times higher than the highest measured value for the
same gene among the triazole susceptible control isolates (underlined value).
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(abcA, abcC, atrF, and atrI). Additionally, disruption of abcC has previously been
demonstrated to increase triazole susceptibility in both susceptible laboratory strains and
a triazole-resistant clinical isolate. [25, 42-44, 66]
To assess the whether the constitutive expression of each the identified efflux
pump-encoding genes of interest may be greater among triazole-resistant clinical isolates
of A. fumigatus, we obtained twenty-six clinical isolates from the Fungus Testing
Laboratory in San Antonio, Texas. This collection of isolates includes five triazolesusceptible clinical isolates, and twenty-one triazole-resistant clinical isolates that have
MIC for at least two triazole agents above published CLSI epidemiological cut-off values
(ECV; voriconazole, isavuconazole, and itraconazole 1mg/L, posaconazole
0.25mg/L).[73, 82] RNA was then isolated from each clinical isolate in biological
triplicate following overnight growth in Aspergillus minimal media at 37°C on an orbital
shaker at 250 RPM, and transcriptional profiling was performed. Normalized read counts
were for each sample were compared to the read counts measured in the triazolesusceptible control isolate DI16-6 (voriconazole MIC 0.25mg/L) to generate fold change
values for each of the efflux pump-encoding genes of interest (Table 3-2).
Of the twelve efflux pump-encoding genes of interest, six were observed to be
expressed at least 2-fold higher in one or more triazole-resistant isolate, as compared to
the triazole-susceptible isolate with the highest measured level of expression for each
gene of interest (abcA, abcC, Afu1g17440, atrI, Afu6g08020, and Afu3g01400). Ten
resistant isolates were observed to overexpress more than one gene of interest, and this
was more frequently observed among more highly triazole resistant clinical isolates.
abcA, which has been shown to increase triazole resistance when overexpressed in a
triazole-susceptible laboratory strain and which has the highest degree of homology with
C. albicans Cdr1, was observed to be overexpressed in eight triazole-resistant clinical
isolates (3.3 to 238.6-fold that of DI16-6). abcC, which has previously been shown to
contribute to clinical triazole resistance in A. fumigatus, was overexpressed in three
triazole-resistant clinical isolates (6.3 to 83.4-fold that of DI16-6). Afu1g17440, which
has not previously been implicated in triazole resistance, was overexpressed in seven
triazole-resistant clinical isolates (2.2 to 8.7-fold). atrI, which when deleted in a triazolesusceptible laboratory strain of A. fumigatus leads to hyper-susceptibility, was
overexpressed in five triazole-resistant isolates (3.3 to 8.3-fold that of DI16-6).
Afu6g08020 and Afu3g014000 have not previously been associated with triazole
resistance and were overexpressed in eight (3.2 to 22.4-fold that of DI16-6) and one (2.3
fold that of DI16-6) triazole-resistant isolates, respectively. As abcA and atrI both have
previously been implicated in triazole resistance, were both found to be overexpressed in
multiple triazole-resistant isolates in this collection, and have not yet been demonstrated
to contribute to triazole resistance among clinical isolates of A. fumigatus, these efflux
pump-encoding genes were selected for further interrogation.
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Deletion of the Efflux Pump-Encoding Genes abcA and atrI Has Minimal Impact on
Clinical Triazole Resistance
Following the identification of abcA and atrI as the efflux pump-encoding genes
of greatest interest, we sought to characterize the direct impact of these two genes on
triazole resistance in clinical isolates of A. fumigatus. To accomplish this, we utilized a
Cas9-mediated transformation system to delete abcA and atrI in triazole-resistant clinical
isolates observed to exhibit constitutive overexpression of each of these genes.[67] As
eight resistant clinical isolates were observed to exhibit overexpression of abcA (at least
2-fold above the highest expression among triazole-susceptible isolates), and seven of
these were found to be statistically significant (as compared to DI16-6; Figure 3-1A), we
selected both DI15-100 (19-fold the abcA expression of DI16-6) and DI15-106 (6.6-fold
the abcA expression of DI16-6) for deletion of abcA. Importantly, DI15-110 (238.6-fold
the abcA expression of DI16-6) was not selected as this isolate exhibits a slow growth
rate, altered growth morphology, and diminished conidiation, all of which make genetic
manipulations technically challenging. Of the five triazole-resistant isolates observed to
overexpress atrI (at least 2-fold above the highest expression among triazole-susceptible
isolates), all of which were statistically significant as compared to DI16-6 (Figure 3-1B),
DI15-106 (8.1-fold the atrI expression of DI16-6) was selected for deletion of atrI.
Subsequently, two independent, positive transformants were constructed for each gene of
interest as previously described.[67] Triazole MIC for all clinically available agents were
then determined following CLSI methods for the parental triazole-resistant clinical
isolates and all efflux pump-deletion strains.[69]
The voriconazole, isavuconazole, itraconazole, and posaconazole MIC for DI15100, DI-106, and all derivative efflux pump deletion strains are shown in Table 3-3. For
both triazole-resistant clinical isolates, the MIC for voriconazole, isavuconazole, and
itraconazole were greater than previously published ECV. Notably, the voriconazole and
isavuconazole MIC for DI15-106 were above the CLSI recommended testing range (0.03
to 16mg/L) and at least 32-fold above the ECV (1mg/L) for these agents.[69] Deletion of
abcA in either the DI5-100 or DI15-106 clinical isolate backgrounds had no impact on
isavuconazole or posaconazole MIC. In the abcA deletion strains constructed in the DI15100 background (DI15-100_abcA_A and DI15-100_abcA_B), voriconazole MIC were
reduced by one dilution (8 to 4mg/L). In the abcA deletion strains constructed in the
DI15-106 background (DI15-106_abcA_A and DI15-106_abcA_B), itraconazole MIC
were reduced by one dilution (2 to 1mg/L). While these changes in triazole MIC were
reproducible, they are also within the accepted assay error range.[69] Similarly, MIC for
voriconazole, isavuconazole, and itraconazole were unchanged upon deletion of atrI in
the DI15-106 background. Posaconazole MIC were observed to increase by one dilution
(from 0.125 to 0.25mg/L).
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Figure 3-1. Relative expression of abcA and atrI among triazole-resistant clinical
isolates.
A) Expression of abcA in clinical isolates relative to triazole-susceptible isolate DI16-6
B) expression of atrI in clinical isolates relative to triazole-susceptible isolate DI16-6;
Triazole-susceptible isolates shown as open bars, triazole-resistant isolates shown as
filled bars. Triazole-resistant isolates shown in order of escalating voriconazole MIC
from left to right. Horizontal dotted lines denote highest and lowest expression level
observed among the five triazole-susceptible isolates. Comparisons with the susceptible
control isolate DI16-6 with statistically significant (p<0.05) results are noted with an
Asterix.
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Table 3-3.
Triazole MIC of clinical isolates and derivative efflux pump-encoding
gene deletion strains.
Parent Clinical Isolate or
Derivative Strain
DI15-100
DI15-100_abcA_A
DI15-100_abcA_B
DI15-106
DI15-106_abcA_A
DI15-106_abcA_B
DI15-106_atrI_A
DI15-106_atrI_B

Voriconazole
8
4
4

Triazole MIC (mg/L)
Isavuconazole
Itraconazole
4
4
4
4
4
4

≥32
≥32
≥32
≥32
≥32

≥32
≥32
≥32
≥32
≥32

2
1
1
2
2

Posaconazole
0.125
0.125
0.125
0.125
0.125
0.125
0.25
0.25

MIC shown in bold are greater than epidemiologic cutoff values as published by the
Clinical Laboratory and Standards Institute (1mg/L for voriconazole and itraconazole;
0.25mg/L for posaconazole).
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Conclusions
In this work we attempted to identify efflux pump-encoding genes which may
contribute to triazole resistance in clinical isolates of A. fumigatus. We identified twelve
efflux pump encoding genes in the Af293 reference A. fumigatus genome with predicted
peptides sequences that have the highest degree of homology with the well characterized
C. albicans triazole efflux pump Cdr1. Importantly, four of the identified genes of
interest have previously been associated with triazole resistance, and one of these, abcC,
has been demonstrated to directly contribute to clinical triazole resistance. [25, 42-44, 66]
The remaining eight genes have not previously been well characterized.
We then performed transcriptional profiling on a collection of twenty-one multitriazole-resistant clinical isolates of A. fumigatus, as well as five triazole-susceptible
control clinical A. fumigatus isolates, to identify which of these efflux pump-encoding
genes are constitutively overexpressed among triazole-resistant clinical isolates.
Transcriptional profiling revealed that six of the twelve efflux pump-encoding genes of
interest were more highly expressed among triazole resistant isolates. These six genes
included abcA, abcC, and atrI, which have previously been implicated in triazole
resistance, as well as Afu1g17440, Afu6g08020, and Afu3g01400 which have not.
Interestingly, ten triazole-resistant isolates were observed to overexpress two or more
genes of interest, and this was observed more frequently among isolates which are more
highly triazole-resistant. Additionally, atrF, which has also previously been implicated in
triazole resistance, was not observed to be more highly expressed among the triazoleresistant isolates in this collection.
We subsequently identified both abcA and atrI as the genes of greatest interest for
further investigation, due to both the observed degree of overexpression among triazoleresistant isolates in our collection, and the findings of previous studies implicating these
genes in clinical triazole resistance. Surprisingly, upon deletion of abcA in both the DI15100 and DI15-106 triazole-resistant clinical isolate backgrounds, no pronounced change
in triazole susceptibility was observed. Similarly, when atrI was deleted in the DI15-106
background, no decrease in triazole resistance occurred. Yet, it remains possible that that
these highly triazole-resistant clinical isolates harbor multiple triazole resistance
mechanisms, such as mutations in the sterol-demethylase gene cyp51A, which may mask
smaller changes in triazole susceptibility upon deletion of the efflux pump encoding
genes of interest. In fact, in previous studies we have shown that DI15-100 and DI15-106
both harbor mutations in cyp51A (encoding M263I and TR46/Y121F/T289A,
respectively). However, we have also demonstrated that correction of these cyp51A
mutations in DI15-100 and DI15-106 also failed to restore the MIC of any triazole agent
to wild-type susceptible ranges.
Taken together, the findings of this study serve to demonstrate that A. fumigatus
efflux pump-encoding genes with homology to known triazole resistance genes are
constitutively overexpressed among triazole-resistant clinical isolates. However, deletion
of either abcA or atrI in resistant clinical isolates which constitutively overexpress them
was insufficient to significantly restore triazole susceptibility. Future studies are needed
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to further characterize the potential role of these and other A. fumigatus efflux pumpencoding genes in clinical triazole resistance, the genetic determinants which lead to
increased efflux pump gene expression among triazole-resistant clinical isolates of A.
fumigatus.
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CHAPTER 4. MUTATIONS IN THE ASPERGILLUS FUMIGATUS HMG-COA
REDUCTASE GENE, HMG1, A NOVEL GENETIC DETERMINANT OF
CLINICAL TRIAZOLE RESISTANCE*
Introduction
The most common invasive mold infection is invasive aspergillosis, with
Aspergillus fumigatus being identified as the etiological agent for more than 72% of all
cases.[2] Worldwide invasive aspergillosis is implicated in more than 200,000 lifethreatening infections each year, and is estimated to affect more than 10% of all patients
with acute leukemia or having received bone marrow or other transplants.[1] While
substantial healthcare resources are allocated to the treatment of invasive aspergillosis,
rates of clinical failure remain unacceptably high, approximating 40%.[4, 83, 84]
The triazole class of antifungals are essential to the treatment of invasive
aspergillosis. Routinely relied upon as both front-line (voriconazole and isavuconazole)
and salvage (itraconazole and posaconazole) therapeutic options, these agents are
available in a range of oral and intravenous formulations and generally are well
tolerated.[10, 13, 79] The triazoles exert fungicidal activity against Aspergillus through
the inhibition of the biosynthesis of ergosterol, and essential constituent of fungal cell
membranes.[21] The triazoles impede ergosterol biosynthesis through competitive
inhibition of the sterol-demethylase proteins, Cyp51A and Cyp51B. Inhibition of these
two enzymes ultimately leads to a depletion of cellular ergosterol and the accumulation
of methylated ergosterol precursors.[14] Unfortunately, the treatment of invasive
aspergillosis has been further complicated by the emergence of A. fumigatus isolates
resistant to the triazoles. While the rate of triazole resistance in the United States is
currently estimated to be 5%, globally reports of triazole-resistant A. fumigatus clinical
isolates are increasing. In countries such as the United Kingdom and the Netherlands,
where triazole resistance rates were previously comparable to those in the United States,
resistance rates now exceed 15%.[6-8, 30]
A limited number of triazole resistance mechanisms have been identified in A.
fumigatus, largely mirroring mechanisms of triazole resistance previously identified in
other pathogenic fungi such as Candida albicans. Single nucleotide polymorphisms
(SNPs) resulting in amino acid substitutions in one of the two sterol-demethylase
enzymes, Cyp51A, overexpression of the gene encoding this sterol-demethylase enzyme,
cyp51A, and overexpression of the efflux pump-encoding gene, abcC, have all been
shown to contribute to triazole resistance among clinical isolates of A. fumigatus.[25, 28,
34, 35, 42-44, 48, 66, 71, 79] However, we have previously demonstrated that these
----------------* Modified from final submission with permission. Rybak JM, Ge W, Wiederhold NP,
Parker JE, Kelly SL, Rogers PD and Fortwendel JR. Mutations in hmg1, challenging the
paradigm of clinical triazole resistance in Aspergillus fumigatus. MBio. 2019 Apr
2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19

44

mechanisms alone poorly explain the high level of triazole resistance observed among
many clinical isolates of A. fumigatus. Thus, the molecular mechanisms underpinning
much of the clinical resistance to this essential class of anti-Aspergillus agents remains
unexplained, limiting the discovery of therapeutic strategies to overcome triazoleresistant aspergillosis.
We describe here for the first time a novel mechanism of triazole resistance, not
mediated by mutations in sterol-demethylase and never before observed among
pathogenic fungi, which was found to be present in a majority of triazole-resistant clinical
isolates of A. fumigatus in our collection. Mutations in the 3-hydroxy-3-methyl-glutarylcoenzyme A (HMG-CoA) reductase encoding gene, hmg1 (Afu2g03700), were found to
result in dramatically increased resistance to all clinically available triazole agents.
Additionally, the restoration of hmg1 to the wild-type sequence in a clinical A. fumigatus
isolate exhibiting high-level pan-triazole resistance was found to restore clinical
susceptibility to the triazole class. We demonstrate that mutations in hmg1 result in
maintained or even increased ergosterol production as well as accumulation of multiple
ergosterol precursors, including eburicol, the substrate of the sterol-demethylase enzymes
which the triazole antifungals competitively inhibit.
Materials and Methods
Isolates, Media, and Growth Conditions Used
Twenty-one previously characterized multi-triazole-resistant clinical isolates of A.
fumigatus, and five triazole-susceptible control clinical isolates of A. fumigatus,
originating from the United States were obtained from the Fungus Testing Laboratory at
the University of Texas in San Antonio.[8] The laboratory strains akuBKU80 and Af293
were obtained from the Fungal Genetics Stock Center. All strains and clinical isolates
used in this study were maintained on glucose minimal media (GMM) agar at 37°C.
Transformants were selected for using sorbitol (1.2M) supplemented GMM agar (SMM)
containing 150mg/L of hygromycin. All conidia were harvested in sterile water from
three-day-old growth plates and conidia were enumerated visually using a
hemocytometer.
Construction of Allele Replacement Repair Templates and Cas9-RNP for the hmg1
Locus
Two component repair templates consisting of a split hygromycin resistance
marker (hphR) and hmg1 alleles of interest were prepared by PCR. Briefly, hmg1 alleles
of interest including the open reading frame and approximately 500 downstream bases
were amplified by PCR from DI15-98 (S305P), DI15-100 (I412S), DI15-105 (F262del),
and akuBKU80 (wild-type control) using a 3’ primer which introduced the terminal 80
bases with homology to the 3’ end of the hphR hygromycin B resistance gene open
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reading frame. A partial hygromycin B resistance cassette, including the gdpA promoter
and a truncated hphR gene lacking the terminal 40 bases, was then amplified by PCR
from the pUCGH plasmid using primers that introduced approximately 70 bases of
homology with the downstream region of hmg1. PCR products were subsequently
purified using the Gene Clean II Kit (MP Biomedicals). Cas9-RNP complexes targeting
sequences immediately upstream and approximately 500 bases downstream of the open
reading frame of hmg1 were assembled as previously described.[67] Target specific
guide sequences and primers are listed in Table 4-1.
Aspergillus Protoplast Transformations
Transformation of A. fumigatus protoplasts were performed as previously
described with minor modifications.[67] Approximately 2μg of each portion applicable
transformation repair templates were then mixed with 200 μL of protoplasts, 26.5 μL of
Cas9-RNP complexes, and 25 μL of polyethylene glycol (PEG)-CaCl2 buffer (60%
[wt/vol] PEG 3350, 50 mM CaCl2·H2O, 450 mM Tris-HCl, pH 7.5) as previously
described. Following an incubation on ice for approximately one hour, 1.25mL PEGCaCl2 was added and the mixture incubated for an additional 20 minutes at room
temperature. The mixture was then diluted to a total volume of 3 mL with STC buffer
(1.2 M sorbitol, 7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM
agar plates. Plates were then incubated overnight prior to being overlaid with SMM top
agar (GMM supplemented with 1.2 M sorbitol and 0.7% [wt/vol] agar) supplemented
with hygromycin (final concentration of 150 g/ml), and the plates were incubated at 37°C
for 3 days. Transformants were isolated to separate plates containing selective agar,
genomic DNA extracted, and successful CRISPR/Cas9 editing confirmed by PCR
screens using gene-specific primers and Sanger sequencing.
Clinical Antifungal Susceptibility Testing
Susceptibilities for amphotericin B, voriconazole, isavuconazole, itraconazole,
and posaconazole were determined for all isolates in accordance with CLSI M38-A2
methodology utilizing broth microdilution in RPMI.[69] Each antifungal was obtained
from the appropriate manufacturer. All agents were suspended in dimethyl sulfoxide
(DMSO) for preparation of stock solutions.
Comprehensive Sterol Profiling.
Fresh conidial suspensions of each strain to be studied were prepared in saline
with tween 80 from AMM agar plates. Conidia were grown in 25mL RPMI supplemented
with 0.2% glucose buffered to pH 7.0 with MOPS for 24 hours in an orbital shaker at 180
RPM and 35°C. Cells were then flash frozen using liquid nitrogen, dry weights obtained,
and alcoholic KOH was utilized to extract nonsaponifiable lipids. A vacuum centrifuge
(Heto) was then used to dry samples, prior to being derivatized by the addition of 200μL
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Table 4-1.

Oligonucleotides used for hmg1, cyp51A, and cyp51B experiments.

Oligo Type
PCR Primers

Gene

Primer Name

Sequence (5'- 3')

hmg1

hmg1 F

hmg1

hmg1 split hphR R

hphR

hphR split F

hphR

hphR 3’UTR hmg1 R

hmg1

hmg1 screen F

CCCACCTGGGATGAAGCAAAAGCGGGTA
CATAGATAGGTTTATGGGGACTTTGGGA
AGTGAAATATGGGCGAGCTCCCAAATCT
GTCCAG
GGTGTCCGTGGTTCCCACC

hphR

hphR screen R

CAAATCGCCCGCAGAAGCG

hmg1 5’ crRNA

ATTTTGTCTATGATAGACAA

hmg1

hmg1 3’ crRNA

CCAACGATTGCCAAAGGTCA

cyp51A

cyp51A RT F e1

CTTCTTTGCGTGCAGAGA

cyp51A

cyp51A RT R e2

GGGGTCGTCAATGGACTA

cyp51B

cyp51B RT F e1

CTTTTTCGACTGCCGCGC

cyp51B

cyp51B RT R e2

AGGCGTAGTGAGTGGAGA

crRNA Guide Sequences
hmg1

GACAGGCGGCTTACACCGCCTCTCCTGCT
CGCCATTTTGTCTATGATCACTGATGGCT
ACCTCTCTGATT
TCTGGACCGATGGCTGTGTAGAAGTACT
CGCCGATAGTGGAAACCGACGCCCCAGC
ACTCGTCCGAGGGCAAAGGAATAGGCTG
CGTTACTCGGTCTTGG
CCACTATCGGCGAGTACTTCTACAC

RTqPCR Primers
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of anhydrous pyridine (Sigma), 100μL of N,O- bis(trimethylsilyl)trifluoroacetamide
(BSTFA)- 10% trimethylsilyl (TMS) (Sigma), and two hours of heating at 80C. Gas
chromatography-mass spectrometry (GC-MS) (Thermo 1300 GC coupled to a Thermo
ISQ mass spectrometer; Thermo Scientific) was then used to analyze and identify TMSderivatized sterols. Known standards were referenced for fragmentation spectra and
retention times. Sterol profiles for each isolate were then created using Xcalibur software
(Thermo Scientific) to analyze GC- MS data.[16] Statistical analysis of both sterol
profiles and total ergosterol per dry weight were performed using GraphPad Prism 7. In
all cases, 6 independent biological replicates were measured and included in analysis,
two-tailed unpaired t-test were performed in Prism 8 for Mac OS by GraphPad Software
Inc. with significance set at 0.05 and degrees of freedom equal to 10.
Assessment cyp51A and cyp51B Expression by RTqPCR
Conidia from each strain were allowed to germinate overnight on an orbital
shaker at 250 RPM incubated at 37°C in Aspergillus minimal media. RNA was then
extracted from mature hyphae following liquid nitrogen crush as previously
described.[68] cDNA was synthesized using the RevertAid RT kit (Thermo Scientific). A.
fumigatus cyp51A and cyp51B were amplified from cDNA by PCR using PCR master
mix and SYBR per the manufacturer’s instructions. Table 4-1 lists the gene specific
primers used for PCR. Conditions used for PCR were as follows: AmpliTaq Gold
activation at 95°C for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds and
annealing/ extension at 60°C. The dissociation curve and threshold cycle (CT) was
determined using the CFX96 Real Time PCR system (Bio-Rad). Changes in gene
expression among isolates were then calculated using the 2-ΔΔCT method. All
experiments were performed in triplicate from biological triplicates. As previously
described, ΔCT values were used to calculate the standard error.[68] Statistically analysis
was performed using unpaired, two-tailed, students t-test in Prism 8 for Mac OS by
GraphPad Software Inc. with significance set at 0.05 and degrees of freedom equal to 10.
Results
Mutations in hmg1 Are Common Among Triazole-Resistant Clinical Isolates of A.
fumigatus
Following our prior findings that the previously characterized mechanisms of
triazole-resistance did not explain the high level of triazole resistance observed in this
collection of clinical A. fumigatus isolates, we sought to interrogate the previously
generated whole genome sequencing data to identify novel mechanisms of resistance. As
the triazoles exert antifungal activity through the inhibition of biosynthesis of the
predominant fungal membrane sterol, ergosterol, initial whole genome sequencing
analysis targeted genes encoding proteins known to participate in ergosterol biosynthesis.
In addition to the previously identified cyp51A mutations, mutations unique to triazoleresistant isolates were also observed in erg3B (Afu2g00320), erg3C (Afu8g01070),
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erg4B (Afu1g07140), erg5 (Afu1g03950), and erg6 (Afu4g03630). However, mutations
occurred in these genes among only a small number of the clinical isolates (Table 4-2).
Intriguingly, 11 of the 21 triazole-resistant clinical isolates (52%) were found to possess
mutations in the hmg1 gene resulting in peptide sequence changes not observed among
the triazole-susceptible control isolates (Figure 4-1A). The A. fumigatus hmg1 gene
encodes a HMG-CoA reductase enzyme previously reported to be essential. HMG-CoA
reductase catalyzes the first committed step in ergosterol biosynthesis and has previously
been shown in other eukaryotic organisms to participate in the regulation of sterol
biosynthesis through direct interactions between sterols and a conserved sterol sensingdomain.[85-88] Of particular interest, eight of the eleven isolates with hmg1 mutations
were found to have mutations affecting residues predicted to reside within the conserved
sterol-sensing domain of Hmg1 (Figure 4-1B). We additionally accessed publicly
available whole genome sequencing data for 11 triazole-resistant clinical isolates
(https://www.ebi.ac.uk/arrayexpress/experiments/E-SYBR-1/samples/) and found 5 to
have mutations in hmg1, 2 of which alter residues in the predicted sterol sensing domain
(P309L and I412T). As mutations in hmg1 were observed in a large proportion of clinical
triazole-resistant isolates, and hmg1 mutations have previously been observed among
laboratory isolates of A. fumigatus grown in the presence of triazole antifungals and the
closely related agricultural sterol-demethylase inhibitors, the observed mutations in hmg1
were selected for further interrogation.[47, 89]
Mutations in hmg1 Confer Resistance to the Triazole Class of Antifungals
To test the hypothesis that mutations in hmg1 directly contribute to clinical
triazole resistance in A. fumigatus, three mutations encoding amino acid substitutions or
in-frame codon deletions in different transmembrane regions of the predicted hmg1
sterol-sensing domain (F262del, S305P, and I412S) were selected for characterization
(Figure 4-1B). Each of these mutations and a wild-type control allele were directly
introduced to the native hmg1 locus of the triazole-susceptible laboratory strain akuBKU80
using a novel Cas9-RNP editing technique incorporating a split hygromycin B resistance
marker (Figure 4-2). Briefly, hmg1 alleles including the open reading frame and
approximately 500 downstream bases were amplified by PCR from DI15-98 (S305P),
DI15-100 (I412S), DI15-105 (F262del), and akuBKU80 (wild-type control) using a 3’
primer which introduced the terminal 80 bases with homology to the 3’ end of the hphR
hygromycin B resistance gene open reading frame. A partial hygromycin B resistance
cassette, including the gdpA promoter and a truncated hphR gene lacking the terminal 40
bases, was then amplified by PCR from the pUCGH plasmid using primers that
introduced approximately 70 bases of homology with the downstream region of
hmg1.[90] Protoplasts of akuBKU80 were then transformed with RNP complexes,
consisting of Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately
upstream and and approximately 500 bases downstream of the open reading frame of
hmg1, and 2μg of each portion of the split marker repair template (a single hmg1 allele
and the truncated hygromycin B resistance cassette), to produce hmg1 mutant strains
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Figure 4-1. Mutations in hmg1 observed in this collection of triazole-resistant
clinical A. fumigatus isolates.
A) hmg1 mutations observed in each clinical isolate relative to the Af293 reference
genome, with mutations affecting residues predicted to reside within the conserved sterolsensing domain shown in bold. B) Schematic depicting the predicted transmembrane
domains of A. fumigatus Hmg1. Residues in light blue comprise the predicted sterolsensing domain, residues in dark blue represent those affected by hmg1 mutations
observed in this collection of clinical isolates, residues shown in green represent those
affected by hmg1 mutations observed in this collection of clinical isolates and further
characterized in this work.
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Figure 4-2. Schematic of Cas9 ribonucleoprotein (RNP) editing technique
incorporating a split hygromycin B resistance marker for creation of hmg1 mutant
strains.
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akuBKU80_hmg1F262del, akuBKU80_hmg1S305P, akuBKU80_hmg1I412S, and akuBKU80_hmg1WT.
Antifungal susceptibility testing was subsequently performed for akuBKU80 and
each of the derivative strains for voriconazole, isavuconazole, itraconazole, posaconazole
and amphotericin B according to the Clinical Laboratory Standards Institute M38-A2
standards (Figure 4-3A).[69] The parental akuBKU80 strain was susceptible to all agents
with MIC of 0.25, 0.5, 0.125, 0.06, and 0.5 mg/L for voriconazole, isavuconazole,
itraconazole, posaconazole, and amphotericin B, respectively. The akuBKU80_hmg1WT
control strain exhibited MIC exactly matching those of the parental strain. Conversely, all
strains harboring a clinically derived mutation in hmg1 were found to exhibit a 4 to 8-fold
increase in MIC for all tested triazoles, exceeding the CLSI reported epidemiologic cutoff values for at least one agent in each mutant strain.[73, 82] Notably amphotericin B
MIC were observed to decrease by two-fold in both the akuBKU80_hmg1S305P and
akuBKU80_hmg1F262del strains (0.5 versus 0.25mg/L), but not in akuBKU80_hmg1I412S.
In an effort to delineate the extent of hmg1-mutation-mediated triazole resistance
within a clinical isolate from our collection, the mutant hmg1 allele in the pan-triazoleresistant clinical isolate DI15-105 was replaced with the wild-type hmg1 allele from
akuBKU80 using the same Cas9-RNP-mediated gene editing described above. The
resultant DI15-105_hmg1WT strain exhibited complete restoration of triazole
susceptibility with an eight-fold or greater decrease in MIC for each triazole agent
(Figure 6b). Intriguingly, the amphotericin B MIC was observed to increase by two-fold
in DI15-105_hmg1WT relative to DI15-105 (0.125 versus 0.25mg/L).
Mutations in hmg1 Lead to Accumulation of Ergosterol Precursors
As the sterol-sensing domain of HMG-CoA reductase has previously been shown
to interact with ergosterol precursors and participate in the negative regulation of HMGCoA reductase activity in both human cells and the model fission yeast
Schizosaccharomyces pombe, we hypothesized that the mutations identified in the sterol
sensing domain of A. fumigatus hmg1 may be leading to dysregulation of the ergosterol
biosynthesis pathway resulting in the observed triazole resistance (Figure 4-4A).[85-88]
To test this hypothesis, comprehensive sterol profiling including assessment of the
relative distribution of cell sterols and the measurement of total ergosterol content per dry
weight was performed on akuBKU80, akuBKU80_hmg1F262del, akuBKU80_hmg1S305P,
akuBKU80_hmg1I412S, akuBKU80_hmg1WT.
To assess the relative distribution of sterols among A. fumigatus harboring hmg1
mutations, freshly harvested conidia stocks of each strain were grown in six biological
replicates in RPMI media supplemented with 0.2% glucose and buffered with MOPS (pH
7.0) for 24 hours before cells were flash frozen with liquid nitrogen, dry weights were
obtained, and nonsaponifiable lipids were extracted, derivatized, and analyzed by gaschromatography mass spectrometry as described previously.[16, 91] In agreement with
the hypothesis that mutations in hmg1 precipitate dysregulation of the ergosterol
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Figure 4-3. Impact of hmg1 mutations on antifungal susceptibility.
A) Triazole MIC for akuBKU80 and derivative mutant hmg1 strains B) Triazole MIC for
DI15-105 and derivative hmg1WT strain.
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Figure 4-4. Relative distribution of sterols and total ergosterol content of hmg1
mutant strains.
A) A. fumigatus ergosterol biosynthetic pathway B) Relative fold change of cellular
sterols lanosterol, eburicol, 4,4-dimethyl ergosta 8,24(28) dienol, fecosterol, episterol,
and ergosterol in hmg1 mutant strains as compared to the parental akuBKU80 strain C)
Total cellular ergosterol per dry weight for hmg1 mutant strains and the parental
akuBKU80 strain. Comparisons with the susceptible parental isolate akuBKU80 with
statistically significant (p<0.05) results are noted with an Asterix.
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biosynthetic pathway, the distribution of sterols was dramatically altered in all hmg1
mutant strains relative to akuBKU80 (Figure 4-4B). Most notably, a significant decrease in
the relative proportion of ergosterol, along with corresponding increases in the
proportions of several ergosterol precursors downstream of Hmg1, including eburicol,
4,4-dimethyl ergosta 8,24(28) dienol, and fecosterol, were observed in all mutant hmg1
strains. Additionally, the relative proportion of episterol was observed to be significantly
elevated in akuBKU80_hmg1F262del and akuBKU80_hmg1S305P. Importantly, no significant
differences in the relative distribution of sterols was observed between akuBKU80 and
akuBKU80_hmg1WT (not shown).
While the distribution of cellular sterols among A. fumigatus harboring hmg1
mutations demonstrated a significant decrease in the relative proportion of cellular
ergosterol, total ergosterol content per dry weight was not lower among any of the mutant
hmg1 strains (Figure 4-4C). In fact, relative to the parental akuBKU80,
akuBKU80_hmg1F262del was observed to exhibit a significant increase in total ergosterol
(4.56 v. 7.06 μg ergosterol/ mg dry weight; p<0.01). Taken together, these findings
demonstrate hmg1 mutations precipitate a relative increase in ergosterol precursors
downstream of Hmg1, while maintaining or in some cases even increasing cellular
ergosterol, leading to significantly altered cellular sterol profiles among mutant hmg1
strains.
Mutations in hmg1 Do Not Lead to Increased Expression of Sterol-Demethylase
Genes
As our sterol profiling studies revealed significant accumulations of ergosterol
precursors both upstream and downstream of sterol-demethylase, and we had previously
observed that increased expression of either sterol-demethylase gene contributes to
triazole resistance, we sought to investigate if the triazole resistance associated with
mutations in hmg1 were at least in part mediated by altered expression of steroldemethylase genes. To accomplish this, conidia suspensions of akuBKU80,
akuBKU80_hmg1F262del, akuBKU80_hmg1S305P, akuBKU80_hmg1I412S, and akuBKU80_hmg1WT
were grown in biological triplicate under the same conditions used for sterol profile
analysis, and RNA was extracted from liquid nitrogen-pulverized samples, as previously
described.[68] RTqPCR was then performed to assess expression of the steroldemethylase genes cyp51A and cyp51B among mutant hmg1 strains relative to the
parental akuBKU80. No significant differences in expression of either sterol-demethylase
gene was observed for any of the mutant hmg1 strains or the akuBKU80_hmg1WT control
strain (Figure 4-5). Demonstrating that while mutant hmg1 strains are observed to have
relatively greater proportions of ergosterol precursors, expression levels of both cyp51A
and cyp51B remain unchanged. Thus, resistance in these strains is not due to increased
expression of these genes.
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Figure 4-5. Expression of sterol-demethylase genes is not elevated among mutant
hmg1 strains.
Fold expression of cyp51A and cyp51B in mutant hmg1 strains relative to the parental
akuBKU80 strain as determined by reverse transcription quantitative PCR.
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Conclusions
Here we describe for the first time, a novel and non-canonical mechanism of
triazole antifungal resistance. Identified through whole genome sequencing, mutations in
the HMG-CoA reductase encoding gene, hmg1, were found among the majority of
triazole-resistant A. fumigatus clinical isolates in our collection. Of the observed
mutations, most occurred in the conserved sterol sensing domain of hmg1, which has
been previously demonstrated to participate in the regulation of sterol biosynthesis in
other eukaryotic organisms including S. pombe.[85-88] When three of these clinicallyderived hmg1 mutations were independently introduced into a well characterized triazolesusceptible strain of A. fumigatus using an optimized Cas9-mediated system to replace
the native hmg1 locus, resistance to all clinically available anti-Aspergillus triazole
antifungals greatly increased. To confirm that mutations in hmg1 are a novel mechanism
of clinical triazole resistance, we employed the same system to correct a hmg1 mutation
identified in a pan-triazole resistant clinical isolate of A. fumigatus and observed
restoration of susceptibility to all triazoles.
As the sterol-sensing domain of HMG-CoA reductase has been shown to be
essential to the regulation of sterol biosynthesis, we hypothesized that amino acid
substitutions in this domain of Hmg1 may lead to impaired negative regulation of Hmg1
activity. [85-88] In an effort to test this hypothesis, we performed comprehensive sterol
profiling on the mutant hmg1 strains. This analysis identified significant accumulations of
ergosterol precursors, including eburicol, 4,4-dimethyl ergosta 8,24(28) dienol,
fecosterol, episterol, while total cellular ergosterol content was seen to be maintained, or
in the case of the hmg1F262del mutation, significantly increased. However, this increase in
ergosterol precursors did not result in a subsequent increase in sterol-demethylase
expression levels in any of the mutant hmg1 strains. Thus, hmg1 mutation-mediated
triazole resistance is not the result of increased sterol-demethylase gene expression.
Taken together, the results of this study identify mutations in the A. fumigatus
HMG-CoA reductase gene, hmg1, as a novel and non-canonical genetic determinant of
clinical triazole resistance, present among a large proportion of resistant clinical isolates.
While the exact mechanism by which mutations in the sterol-sensing domain of hmg1
impart clinical triazole resistance remains unknown at this time, it is tempting to
speculate that the negative regulation of Hmg1 activity, which has been shown to be
dependent on the sterol-sensing domain in other eukaryotic organisms, may be altered by
residue substitutions in the sterol-sensing domain of A. fumigatus Hmg1.
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CHAPTER 5.

DISCUSSION

Invasive aspergillosis is a leading cause of morbidity and mortality among
immunocompromised populations and is predicted to cause more than 200,000 lifethreatening infections each year.[1, 4, 83, 84] Aspergillus fumigatus is the predominant
pathogen isolated from patients with invasive aspergillosis, and accounts for more than
60% of all cases.[2] Only three classes antifungal agents are currently available for the
treatment of invasive infections caused by Aspergillus fumigatus. Of these, the triazoles
represent both therapeutic agents of choice, such as voriconazole and isavuconazole, as
well as agents commonly used for salvage therapies such as itraconazole and
posaconazole. As other antifungal agents such as the polyene amphotericin B and the
echinocandins possess limitations in formulation, safety profile, or lack consistent
fungicidal activity against A. fumigatus, the triazoles have proven to be essential to the
treatment of invasive aspergillosis. Thus, the recent emergence of triazole-resistant A.
fumigatus represents a critical threat to the current treatment of invasive aspergillosis.[10]
While considerable research has been performed to interrogate the mechanisms by
which A. fumigatus becomes resistant to triazole antifungals, the overwhelming majority
of resistance has been ascribed to three canonical paths that were originally described
among pathogenic fungi decades ago; 1) mutations in sterol-demethylase genes, 2)
overexpression of sterol-demethylase genes, or 3) overexpression of efflux pumpencoding genes. [25, 28, 34, 35, 42-44, 48, 66, 71, 79] Of these three paths, mutations in
the A. fumigatus sterol demethylase gene cyp51A are the most commonly reported in the
literature. However, the proportion of clinical triazole resistance explained by these
canonical pathways remains poorly characterized. Additionally, resistant clinical isolates
exhibiting none of these previously identified mechanisms have been reported.[25] This
gap in the current understanding of the molecular mechanisms underpinning clinical
triazole resistance in A. fumigatus is a significant barrier to the preservation of the utility
of the triazoles and the design of novel therapeutic strategies to overcome triazoleresistant aspergillosis. The overall objective of this work was to overcome this barrier by
performing a comprehensive characterization of the direct contributions of previously
identified mechanisms of triazole resistance in a large collection of highly triazoleresistant clinical A. fumigatus isolates, and to identify novel mechanisms where
unexplained clinical resistance was found.
In Chapter 2 we sought to test the hypothesis that the previously identified
mechanisms of triazole resistance do not fully account for the degree of triazole
resistance observed among clinical isolates of A. fumigatus. To accomplish this, we
utilized a large collection of triazole-resistant clinical A. fumigatus isolates and whole
genome sequencing, to identify all mutations in the sterol-demethylase genes cyp51A and
cyp51B, and well the previously identified sterol-demethylase cis- and trans-regulatory
elements. While no mutations unique to resistant isolates were identified in cyp51B,
unique mutations in cyp51A were found in the vast majority of resistant isolates.
However, correction of ten of these cyp51A mutations to the wild-type sequence only
partially or fully restored clinical triazole susceptibility in two and one clinical isolate
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background, respectively. Additionally, RTqPCR revealed significant overexpression of
cyp51A was observed in eight of the twenty-one triazole resistant isolates, five of which
had mutations in either the promoter of cyp51A or a known transcriptional regulator of
cyp51A (hapE). However, we subsequently demonstrated that the constitutive
overexpression of either sterol-demethylase gene by as much as thirty-five-fold, had a
limited impact on triazole susceptibility in a triazole-susceptible laboratory isolate. Next,
we examined the expression of the previously characterized A. fumigatus triazole efflux
pump abcC in our collection of isolates by RTqPCR. Fourteen of the twenty-one triazoleresistant clinical isolates were observed to have significantly increased expression of
abcC. However, the majority of these isolates only exhibited a small increase in abcC
(2.4 to 4.1-fold) while only three were found to have more marked increases in
expression (6.5 to 33.2-fold), and constitutive overexpression of abcC (7.8-fold) in a
triazole-susceptible laboratory strain yielded no change in triazole susceptibility. These
findings serve to highlight the fact that even when considered collectively, the previously
characterized mechanisms of resistance do not adequately explain the triazole resistance
observed in this collection of A. fumigatus clinical isolates, and additional mechanisms
yet to be identified are likely present in this collection.
Subsequently, in Chapter 3 we tested the hypothesis that the constitutive
overexpression of efflux pump-encoding genes, other than abcC, directly contributes to
clinical triazole resistance in A. fumigatus. To accomplish this, we utilized the collection
of clinical A. fumigatus isolates we had previously characterized and transcriptional
profiling to identify a subset of A. fumigatus efflux pump-encoding genes with a high
degree of homology to the well characterized C. albicans triazole efflux pump Cdr1,
which were uniquely, constitutively overexpressed among triazole-resistant clinical
isolates. We then identified abcA and atrI as the genes of greatest interest, and utilized
Cas9-mediated genetic manipulations to delineate the direct contributions of these genes
to triazole resistance. Unexpectedly, we found that deletion of these genes in triazoleresistant clinical isolates known to overexpress them, did not to result in meaningful
changes in triazole susceptibility. However, it is worth noting that these results may have
been limited by the presence of additional resistance mechanisms in these isolates, such
as cyp51A mutations. While these findings could not definitively demonstrate a role for
either abcA or atrI in clinical triazole resistance, they do serve to demonstrate the
potential for additional efflux pump-encoding genes to participate in clinical triazole
resistance.
Finally, in Chapter 4 we utilized our previously generated whole genome
sequencing data to test the hypothesis that mutations in genes involved in the
biosynthesis of ergosterol, other than sterol-demethylase, significantly contribute to
clinical triazole resistance. Following careful examination of our whole genome
sequencing data, we identified numerous genes of the ergosterol biosynthesis pathway
(erg3B, erg3C, erg4B, erg5, erg6, and hmg1) where mutations unique to triazole-resistant
isolates were present. Of these, we found mutations in the HMG-CoA-reductase gene
hmg1 to be the most intriguing, as the majority of resistant clinical isolates in our
collection were observed to have mutations in this gene, and previous studies in other
eukaryotic organisms such as Schizosaccharomyces pombe have found hmg1 homologs
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to contain conserved sterol sensing domains involved in the regulation of the ergosterol
biosynthesis pathway. Additionally, the majority of the identified hmg1 mutations were
found to reside in the predicted sterol-sensing domain. As these sterol-sensing domain
mutations each fell within one of three predicted transmembrane domains, we selected
one representative mutation from each transmembrane domain and utilized a novel Cas9mediated split marker transformation system to introduce these mutant hmg1 alleles into
a triazole-susceptible laboratory strain of A. fumigatus. Surprisingly, introduction of each
of the three mutant hmg1 alleles to the susceptible stain were found to dramatically
increase MICs for all clinically available triazole agents. Moreover, the complementary
experiment correcting the F262del hmg1 mutation in the hmg1 allele of the pan-triazoleresistant isolate DI15-105 resulted in the restoration of clinical susceptibility to all
triazoles. Thus, proving that mutations in hmg1 are a novel genetic determinant of
clinical triazole resistance in A. fumigatus.
As the sterol-sensing domain of HMG-CoA-reductase enzymes has been shown to
participate in the autoregulation of HMG-CoA-reductase activity, and subsequently the
regulation of ergosterol biosynthesis, we then hypothesized that mutations in the sterolsensing domain of hmg1 lead to dysregulation of ergosterol biosynthesis. To test this
hypothesis, we performed compressive sterol profiling on the cellular extracts from each
of our mutant hmg1 strains and the parental strain with a wild-type hmg1 allele. In
agreement with our hypothesis, sterol profiling revealed that the mutant hmg1 strains
indeed exhibited accumulation of ergosterol precursors downstream HMG-CoAreductase activity, while also maintaining, or in some cases increasing, the total cellular
ergosterol content. This finding was particularly intriguing as it is suggestive of a
potential association between increased hmg1 activity and triazole resistance.
Additionally, HMG-CoA is a validated target for pharmalogical inhibition, and numerous
drugs which inhibit the human form of this enzyme are currently clinically available.
Future studies are needed to further characterize the role of hmg1 mutations in clinical
triazole resistance, and to identify any potential therapeutic strategies for overcoming
triazole resistance associated with these mutations.
While the findings of the studies described herein identify mutations in hmg1 as a
novel genetic determinant of clinical triazole resistance, we have yet to definitively
identify the molecular mechanism(s) by which these mutations contribute to the observed
resistance. It is however tempting to speculate, based upon these data and previously
published findings, that triazole resistance may be the result of two molecular
mechanisms related to altered cell sterol composition. First, the accumulation of
ergosterol precursors such as eburicol, episterol, and fecosterol, as observed in our sterol
profiling experiments, may alter baseline cell membrane characteristics sufficiently to
diminish the impact of sterol-demethylase inhibition. It has been postulated that a portion
of the antifungal effect of triazoles is a consequence of acute changes in membrane
characteristics such as fluidity and integrity upon inhibition of sterol-demethylase
activity. [92] Accumulation of ergosterol precursors, particularly those downstream of the
sterol-demethylase enzymes such as episterol and fecosterol, may augment the impact of
the triazoles on membrane characteristics by either temporarily facilitating continued
ergosterol biosynthesis or through the modification of baseline membrane characteristics.
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Additionally, it is possible that the accumulation of ergosterol precursors indirectly
mediates triazole resistance. Previous studies have shown that the accumulation of sterols
such as eburicol can precipitate activation of stress response pathways similar to those
triggered by exposure to triazole antifungals. [93] Thus, the accumulation of ergosterol
precursors in isolates with mutations in hmg1 may lead to increases in the constitutive
expression of drug resistance effectors, such as efflux pump-encoding genes, and prime
cells to rapidly respond to triazole exposure. However, future studies will be needed to
explore the potential contribution of these molecular mechanisms to hmg1 mutationmediated clinical triazole resistance.
In conclusion, the findings of the work described herein serve to demonstrate that
clinical triazole resistance in A. fumigatus is most likely the result of a complex
amalgamation of resistance mechanisms, including both mechanisms currently known
and yet to be identified. Furthermore, the paradigm of the molecular mechanisms of
triazole resistance established in fungal pathogens such as Candida albicans, offers only
an incomplete explanation for the triazole resistance observed in clinical isolates of A.
fumigatus. The addition of hmg1 mutations to the known genetic determinants of triazole
resistance advances our understanding of the molecular mechanisms underpinning
clinical triazole resistance, yet a substantial proportion of resistance remains to be
explained. Future directions for this work include the characterization of compounded
triazole resistance mechanisms, such as the combination of cpy51A and hmg1 mutations,
as well as the further characterization of efflux pump-encoding genes which are
differentially expressed among triazole-resistant clinical isolates. Additionally, A.
fumigatus Hmg1 must be investigated as a potential target of pharmacological inhibition
and an opportunity to for the development of a new therapeutic strategy to overcome
clinical triazole resistance in A. fumigatus.
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